https://trial.medpath.com/news/2139a451791264cb/global-diabetes-care-market-projected-to-reach-62-73-billion-by-2032-driven-by-rising-disease-prevalence-and-technology-advances 2025-05-10T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/15deec8a982a30b0/ngex-minerals-reports-exceptional-gold-grades-in-phase-3-drilling-at-lunahuasi-project 2025-05-10T08:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/56424e36c1caafb7/lumithera-s-valeda-light-delivery-system-shows-extended-vision-benefits-in-dry-amd-patients-over-4-5-years 2025-05-10T07:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/a2499e4262f10aa9/nelipak-expands-healthcare-packaging-operations-in-costa-rica-with-new-60m-manufacturing-facility 2025-05-10T07:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/49058b0b26adad18/fda-demands-additional-trial-for-novavax-covid-19-vaccine-delaying-full-approval 2025-05-10T04:39:22+00:00 hourly 0.9 https://trial.medpath.com/news/c962521ed002b4c7/aprocitentan-shows-promising-results-in-black-adults-with-resistant-hypertension 2025-05-10T04:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/c2627540670200de/avammune-therapeutics-secures-12m-series-a-funding-to-advance-novel-cancer-immunotherapy 2025-05-10T04:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/850be6dcf2b9027c/lumithera-s-valeda-light-delivery-system-shows-sustained-vision-improvement-in-dry-amd-patients 2025-05-10T04:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/a2bfff96668116e6/tarlatamab-shows-superior-survival-in-small-cell-lung-cancer-key-highlights-from-asco-2025 2025-05-10T04:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/1d70e6501fba5441/braf-p-v600e-mutation-shows-limited-prognostic-value-in-papillary-thyroid-cancer-risk-stratification 2025-05-10T03:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/cacd12794da1b89f/strategic-sequencing-of-t-cell-therapies-in-relapsed-refractory-multiple-myeloma-expert-guidelines 2025-05-10T02:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/78f3a0aee85a023d/taysha-gene-therapies-advances-tsha-102-for-rett-syndrome-with-fda-alignment-on-pivotal-trial-design 2025-05-10T02:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/f874db02d7a5c720/reduced-dose-radiotherapy-shows-promise-for-early-stage-anal-cancer-treatment 2025-05-10T02:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/a3616833532fe3a9/new-cancer-center-at-jfk-university-medical-center-aims-to-enhance-multidisciplinary-care 2025-05-10T02:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/36fb3eb882c35cb7/comprehensive-treatment-strategies-for-epithelioid-sarcoma-from-frontline-approaches-to-disease-progression-management 2025-05-10T02:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/97ec483bbca0c25e/newbiologix-licenses-high-yield-hek293-cell-line-to-recibiopharm-for-advanced-aav-gene-therapy-production 2025-05-10T01:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/fc8ea9fa1ed980ce/biotech-funding-crisis-forces-strategic-pivots-as-vc-investment-remains-challenging-despite-recovery-signs 2025-05-10T01:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/22d9fdca71afad4d/takeda-accelerates-us-investment-strategy-while-advancing-three-pivotal-phase-iii-programs-for-2025 2025-05-10T00:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/a4fcb7e5e0cb6eee/breakthrough-in-als-treatment-canadian-researchers-successfully-bypass-blood-brain-barrier 2025-05-10T00:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/1dc60b81f9c79459/coave-therapeutics-unveils-coaav-csf-01-a-breakthrough-gene-therapy-vector-for-cns-diseases 2025-05-10T00:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/9e5ad33f56c5cec1/plozasiran-shows-promise-in-reducing-cholesterol-and-triglycerides-in-mixed-hyperlipidemia-patients 2025-05-10T00:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/2bf160e8975aa9cd/cns-pharmaceuticals-reports-berubicin-trial-results-in-glioblastoma-patients 2025-05-10T00:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/02af61ace87d28ab/rocket-pharmaceuticals-to-present-first-phase-1-data-for-gene-therapy-in-rare-heart-condition-at-asgct 2025-05-10T00:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/094767da90ecfda4/applied-therapeutics-to-present-extended-inspire-trial-data-for-govorestat-in-sord-deficiency-at-pns-annual-meeting 2025-05-10T00:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/74c08f7442592e94/leucine-rich-bio-expands-global-footprint-launches-bugspeaks-gut-microbiome-test-in-qatar 2025-05-10T00:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/9c7e6feded459a93/biopharma-q1-updates-new-drug-launches-and-fda-extension-for-cytokinetics-aficamten 2025-05-10T00:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/ceeb0d24b3185fa1/digital-health-technologies-and-ai-show-promise-for-transforming-lysosomal-storage-disorder-care-in-europe 2025-05-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9edf2d6a7d18f38/fda-initiates-pdufa-viii-reauthorization-process-with-public-meeting-and-assessment-report 2025-05-09T23:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/5a3a56b827642f8e/durvalumab-combination-shows-disease-free-survival-improvement-in-high-risk-non-muscle-invasive-bladder-cancer 2025-05-09T23:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/00260c2d3db2498f/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-royalty-rates-from-2010-2025 2025-05-09T22:42:02+00:00 hourly 0.9 https://trial.medpath.com/news/928622cde147a387/palatin-technologies-completes-1-1m-public-offering-following-otc-pink-transition 2025-05-09T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/c526cace8e430816/nigerian-firm-codix-bio-secures-first-who-backed-license-to-manufacture-rapid-diagnostic-tests-in-africa 2025-05-09T22:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/c3d11a817a27c6eb/nkgen-biotech-ceo-invests-2-65-million-of-personal-funds-to-advance-alzheimer-s-cell-therapy-trial 2025-05-09T21:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/a2237eb621416713/singapore-s-prl3-zumab-shows-promise-in-phase-ii-trial-for-treatment-resistant-solid-tumors 2025-05-09T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/81ee0e114b2b3d16/hillhurst-bio-secures-6-3-million-in-grants-to-advance-novel-parkinson-s-disease-treatment 2025-05-09T21:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/3951199637c3a7c5/roche-invests-283-million-in-shanghai-biologics-facility-for-eye-disease-treatment 2025-05-09T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/dc34d61495166f37/abvc-biopharma-secures-japanese-patent-for-botanical-depression-treatment-through-2040 2025-05-09T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/b3b86de6b9aa4c7d/nuevocor-secures-us-45-million-series-b-funding-to-advance-gene-therapy-for-genetic-cardiomyopathy 2025-05-09T20:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/3899d4f9c2aaf960/astrazeneca-opens-300-million-cell-therapy-manufacturing-facility-in-rockville-maryland 2025-05-09T20:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/188b2a56615f6fb5/sublocade-shows-promise-as-safe-treatment-option-for-opioid-use-disorder-during-pregnancy 2025-05-09T20:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/1c86d4a7343333c6/novel-immunotherapies-and-targeted-agents-show-promise-in-myelodysplastic-syndromes-treatment-landscape 2025-05-09T20:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/3142db64d11534e9/kelonia-therapeutics-to-present-novel-in-vivo-gene-delivery-system-data-at-asgct-2025 2025-05-09T20:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/28292aecb687cafe/haic-with-folfox-plus-camrelizumab-and-sorafenib-shows-limited-efficacy-in-advanced-hcc 2025-05-09T20:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/269b5596612245c0/protalix-advances-prx-115-gout-treatment-to-phase-ii-following-promising-early-results-and-strong-q1-revenue 2025-05-09T20:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/f38f9a725f7dfe15/eu-proposes-critical-medicines-act-to-address-supply-chain-vulnerabilities-and-reduce-import-dependency 2025-05-09T20:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/e24e521b6846f938/weightwatchers-files-for-bankruptcy-as-glp-1-weight-loss-drugs-reshape-industry 2025-05-09T19:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/bd91a36bbfc8ec13/nkure-and-crispr-therapeutics-partner-to-develop-off-the-shelf-car-t-therapy-for-cancer-in-india 2025-05-09T19:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/e2aae92a70ff6d26/shifting-landscape-5eu-markets-show-significant-changes-in-hta-decisions-and-drug-pricing-in-q1-2025 2025-05-09T19:38:38+00:00 hourly 0.9 https://trial.medpath.com/news/ef6ebeaf64edeb14/systimmune-to-present-promising-data-on-iza-bren-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-05-09T19:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/401566aa21a5055c/leap-therapeutics-halves-workforce-and-refocuses-cancer-drug-development-amid-market-challenges 2025-05-09T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/383af55142ff13a4/minaris-advanced-therapies-launches-as-global-cell-therapy-cdmo-powerhouse 2025-05-09T19:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/56ce206cf3a98244/eli-lilly-reshuffles-executive-leadership-to-accelerate-global-growth-strategy 2025-05-09T18:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/a308784603dd9412/taiwan-s-formosa-pharmaceuticals-signs-exclusive-licensing-deal-with-almac-discovery-for-adc-development 2025-05-09T17:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/f7f9489fdc82c6b6/takeda-spotlights-three-late-stage-readouts-as-potential-inflection-point-amid-vyvanse-generic-competition 2025-05-09T17:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/6c7a15f90e02f83f/target-rwe-showcases-groundbreaking-liver-disease-research-at-easl-congress-2025 2025-05-09T16:43:25+00:00 hourly 0.9 https://trial.medpath.com/news/8a8e9f58b5deba3b/eli-lilly-commits-250-million-to-expand-purdue-university-research-alliance-through-2032 2025-05-09T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/13390475e736a85c/crinecerfont-shows-promise-in-pediatric-congenital-adrenal-hyperplasia-across-all-patient-subgroups 2025-05-09T16:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/2c55c0f7c732a8f0/minghui-and-qilu-pharmaceuticals-partner-on-b7-h3-adc-development-in-210-million-deal-for-greater-china 2025-05-09T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/2a49c7cbcad9de5b/galimedix-advances-oral-gal-101-therapy-for-alzheimer-s-and-eye-diseases-in-phase-1-trial 2025-05-09T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/38244b9794935476/perfuse-therapeutics-per-001-shows-promise-as-first-disease-modifying-treatment-for-glaucoma-in-phase-1-2a-trial 2025-05-09T16:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/a0d329bf4dbcdf78/real-world-study-validates-decisiondx-um-test-with-prame-biomarker-for-improved-uveal-melanoma-risk-stratification 2025-05-09T16:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/1b57ef5b46ecd65a/genefab-and-regcell-partner-to-advance-novel-treg-cell-therapy-for-autoimmune-diseases-into-us-clinical-trials 2025-05-09T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/20c3223a30b7e042/lilly-and-purdue-university-forge-historic-250-million-pharmaceutical-innovation-partnership 2025-05-09T16:40:41+00:00 hourly 0.9 https://trial.medpath.com/news/562d1d18bdd9d903/formosa-pharmaceuticals-secures-exclusive-license-for-novel-bispecific-adc-targeting-egfr-ror1-solid-tumors 2025-05-09T16:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/b7583dae7bcf0b81/insilico-medicine-secures-123-million-series-e-funding-to-advance-ai-driven-drug-discovery-pipeline 2025-05-09T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/news/f35ecd23e20c4789/sirius-therapeutics-secures-50-million-in-series-b2-funding-to-advance-sirna-therapies-for-cardiometabolic-diseases 2025-05-09T16:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/b46f3f6c82ceaf52/new-abiraterone-formulation-shows-equivalent-efficacy-at-lower-dose-for-metastatic-prostate-cancer 2025-05-09T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/1608c3f9a4876522/omrx-oncology-launches-phase-2-trial-of-novel-oral-pd-l1-inhibitor-for-nsclc-targeting-global-access-disparities 2025-05-09T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/6341e04ef2799b5e/east-africa-launches-regional-drug-research-hub-in-kenya-and-expands-health-security-network 2025-05-09T16:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/211cab9c15c1b785/neoadjuvant-scrt-plus-camrelizumab-shows-promising-3-year-survival-in-locally-advanced-rectal-cancer 2025-05-09T16:39:29+00:00 hourly 0.9 https://trial.medpath.com/news/e946bf3237b8a8ab/path-ex-secures-5-million-to-advance-novel-sepsis-treatment-device-cyclope 2025-05-09T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/cc592e74627f3a7e/quanthealth-launches-first-clinical-trial-foundation-model-on-aws-marketplace 2025-05-09T16:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/133bd983481a6d91/think-bioscience-and-crystalsfirst-expand-partnership-to-tackle-undruggable-targets 2025-05-09T16:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/8e2667f242959260/fda-misses-review-deadline-for-gsk-s-nucala-copd-expansion-amid-regulatory-delays 2025-05-09T16:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/224e5579a5bbe793/fda-approves-first-at-home-cervical-cancer-screening-test-expanding-access-to-preventive-care 2025-05-09T16:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/33839d45a061b38e/indonesia-launches-phase-3-trial-of-m72-tuberculosis-vaccine-amid-safety-assurances 2025-05-09T15:57:21+00:00 hourly 0.9 https://trial.medpath.com/news/fdd462c3c23ffdae/optigo-biotherapeutics-develops-long-acting-anti-vegf-therapy-with-six-month-dosing-potential 2025-05-09T15:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/135a2cf30fc903a5/lilly-s-oral-glp-1-orforglipron-shows-promising-results-in-phase-3-trial 2025-05-09T14:38:34+00:00 hourly 0.9 https://trial.medpath.com/news/5c91ca7ff5938f29/leo-pharma-s-temtokibart-shows-promising-results-in-phase-2b-trial-for-moderate-to-severe-atopic-dermatitis 2025-05-09T13:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/a7bef727f1e11540/ema-suspends-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-09T13:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/1f5b09dfc1ae2308/bombay-hc-challenges-cdsco-s-rejection-of-indigenous-cancer-immunotherapy-trial 2025-05-09T12:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/aee52b022041ef50/pharmac-to-fund-advanced-melanoma-treatments-in-new-zealand-starting-june-2025 2025-05-09T12:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/02433e24b6e93fd0/novagold-completes-179-million-public-offering-to-advance-donlin-gold-project-development 2025-05-09T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/23e922eac72527ec/biowell-partners-with-texas-biotechnology-to-create-largest-public-industrial-biomanufacturing-facility-in-the-us 2025-05-09T10:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/a827ce44434ec642/neurofibromatoses-pipeline-shows-strong-activity-with-12-therapies-in-development-across-multiple-clinical-stages 2025-05-09T10:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/b54332a3752fd068/rectify-pharma-s-novel-dual-targeted-pfm-shows-promise-for-hepatobiliary-diseases-at-easl-2025 2025-05-09T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d10b9940220c8453/australian-scientists-develop-breakthrough-mrna-vaccine-strategy-for-decades-long-immunity 2025-05-09T09:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/7afb625d64fd676a/ascidian-therapeutics-advances-rna-exon-editing-platform-with-key-leadership-appointments-and-clinical-progress 2025-05-09T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/61b5fff7e5aed0b7/lenz-therapeutics-and-lotus-pharmaceutical-forge-125-million-deal-for-presbyopia-treatment-in-southeast-asia 2025-05-09T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/30af68cea40f43bc/diabetes-drug-pioglitazone-shows-promising-anti-tumor-effects-in-prostate-cancer 2025-05-09T08:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/b4ceb36057370294/aribio-and-fujirebio-complete-major-biomarker-sample-collection-for-alzheimer-s-research-in-phase-3-polaris-ad-trial 2025-05-09T08:37:55+00:00 hourly 0.9 https://trial.medpath.com/news/c58d279f4889c28f/queen-mary-researchers-develop-novel-model-for-recurrent-glioblastoma-treatment-using-repurposed-antiparasitic-drug 2025-05-09T08:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/0c78d76d1c42eb89/ucb-s-rystiggo-r-rozanolixizumab-approved-in-japan-for-at-home-self-administration-in-gmg-patients 2025-05-09T08:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/9ad04d1ac42b8f2f/rocket-pharmaceuticals-advances-gene-therapy-pipeline-with-key-updates-on-danon-disease-and-pkp2-acm-programs 2025-05-09T08:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/485af0ac8348ce4e/ai-powered-pathology-transforming-cancer-diagnostics-and-precision-oncology 2025-05-09T08:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/7c16e7ee8ccb9131/shionogi-to-acquire-japan-tobacco-s-pharmaceutical-subsidiaries-for-1-1-billion 2025-05-09T08:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/0d0601b38264b151/nice-opens-consultations-for-two-targeted-therapies-in-advanced-non-small-cell-lung-cancer 2025-05-09T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fadc3099a8bd9b3/vivo-capital-secures-740-million-for-third-cycle-of-healthcare-investment-fund 2025-05-09T07:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/b9eb25fa9858cb84/elutia-announces-strong-first-quarter-2025-financial-results-driven-by-84-sequential-growth-in-eluprotm-sales 2025-05-09T07:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/1d7701705bac1026/gsk-s-linerixibat-shows-significant-improvement-in-cholestatic-pruritus-for-primary-biliary-cholangitis-patients 2025-05-09T06:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/efd752f76cdcd87b/novel-blood-test-could-guide-precision-treatment-for-resistant-lupus-with-rituximab-belimumab-combination 2025-05-09T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/168c8ccee61c95da/upmc-enterprises-leads-18-25-million-series-b1-investment-in-carta-healthcare-for-ai-powered-clinical-data-management 2025-05-09T06:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/ead7366c339fa83e/vor-bio-halts-clinical-operations-and-explores-strategic-alternatives-amid-financial-challenges 2025-05-09T06:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/8388d78bb503ce39/ludwig-enterprises-unveils-revealia-breast-a-revolutionary-cheek-swab-test-for-early-breast-cancer-detection 2025-05-09T06:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/a9921c0b451a0fc0/ionq-expands-quantum-computing-portfolio-through-strategic-acquisitions-of-lightsynq-and-id-quantique 2025-05-09T05:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/52280d6f323a65a4/cb-scientific-rebrands-as-cardiac-biotech-solutions-advances-mycardia-at-cardiac-monitor-global-rollout 2025-05-09T05:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/87cf6671b7412560/merck-animal-health-commits-895-million-to-expand-kansas-manufacturing-and-r-d-facilities 2025-05-09T05:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/de589f8f95f9186a/paq-therapeutics-secures-39m-series-b-funding-and-launches-phase-1-trial-for-novel-kras-g12d-degrader 2025-05-09T05:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/6420024f2b9d87ec/disc-medicine-advances-bitopertin-nda-for-erythropoietic-protoporphyria-as-pipeline-progress-continues 2025-05-09T04:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/1d2bd4f3bd1f9561/five-leading-companies-form-lnp-alliance-to-accelerate-nanoparticle-based-drug-development 2025-05-09T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/a632d49f3383aa19/fda-issues-urgent-warning-against-gas-station-heroin-tianeptine-citing-severe-health-risks 2025-05-09T04:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/b62104ffa329fc99/redesign-health-and-cedars-sinai-form-strategic-partnership-to-launch-multiple-healthcare-companies 2025-05-09T04:39:23+00:00 hourly 0.9 https://trial.medpath.com/news/7e005a55ec8728ba/shionogi-and-cilcare-partner-in-eur400m-deal-to-develop-novel-hearing-loss-treatments 2025-05-09T04:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/7ed0d3f42f72c4be/takeda-pledges-30b-in-u-s-argues-against-trumps-most-favored-nations-proposal 2025-05-09T04:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/3411792a04ceb915/tfs-healthscience-and-oncomatryx-advance-novel-fap-adc-to-phase-ib-trial-for-pancreatic-cancer 2025-05-09T04:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3ed54dbd239b758/appeals-court-rejects-astrazeneca-s-challenge-to-medicare-drug-price-negotiation-program 2025-05-09T04:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/b94f3f3df809ccd5/osaka-university-develops-promising-immune-cell-therapy-for-acute-myeloid-leukemia 2025-05-09T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/8f33d95b6adbc01f/new-challenges-emerge-in-transitioning-cidp-patients-from-ivig-to-efgartigimod 2025-05-09T04:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/07cf08268a30cd60/sigachi-industries-secures-european-certification-for-metformin-hydrochloride-api 2025-05-09T04:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/b8386f0719c34640/nppa-sets-retail-prices-for-84-drugs-including-empagliflozin-combinations-following-patent-expiry 2025-05-09T04:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/eecf11d71379cec9/ingenus-pharmaceuticals-advances-cancer-drug-patent-suit-against-nexus-court-dismisses-co-plaintiff 2025-05-09T04:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/a6acc4bd5cf9c1d7/karma-biosciences-files-patents-for-rapid-acting-nasal-pde-5-inhibitors-with-5-minute-onset 2025-05-09T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/535781045f9bd5b9/biovaxys-and-sona-nanotech-partner-to-develop-novel-cancer-immunotherapy-combining-dpx-platform-with-gold-nanorod-technology 2025-05-09T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/9d0024d41af0f297/genezen-and-optieum-partner-to-manufacture-lentiviral-vectors-for-novel-glioblastoma-car-t-therapy 2025-05-09T04:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/321ad97565ace5d1/dawn-health-secures-eur11-5-million-to-expand-pharma-focused-digital-health-platform 2025-05-09T04:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/e5830e1247abe757/leqvio-emerges-as-leading-pcsk9-inhibitor-in-cholesterol-management-across-major-markets 2025-05-09T04:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/5212954c901f3d7f/biocon-reports-15-revenue-growth-in-q4fy25-launches-fifth-biosimilar-in-u-s-market 2025-05-09T04:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/55f8ac8b49911795/nuvalent-advances-toward-first-nda-submission-with-pivotal-data-expected-for-ros1-and-alk-inhibitors-in-2025 2025-05-09T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/ea99892898b07973/moderna-schedules-investor-conference-presentations-for-may-and-june-2025 2025-05-09T04:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/29552af74c251d72/peptone-and-evotec-form-strategic-alliance-to-develop-novel-therapeutics-targeting-intrinsically-disordered-proteins 2025-05-09T04:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/bd72863338aea8e7/schrodinger-reports-63-revenue-growth-in-q1-2025-prepares-to-share-clinical-data-for-sgr-1505 2025-05-09T04:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/d48967e9e9b9b880/lexaria-bioscience-advances-dehydratech-platform-to-enhance-glp-1-drug-effectiveness 2025-05-09T04:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/0c0d46e67acb2e0e/10-year-data-confirms-1-week-radiotherapy-as-effective-as-3-week-course-for-early-stage-breast-cancer 2025-05-09T01:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/120ca2906f08531b/uic-researchers-develop-groundbreaking-antibiotic-against-superbugs-as-illinois-faces-rising-antimicrobial-resistance 2025-05-09T01:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/7767eafb8d2e3b72/utr-therapeutics-submits-ind-for-novel-mrna-destabilizing-drug-targeting-c-myc-in-multiple-cancers 2025-05-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/cde6ab1e7bb2ed97/viatris-advances-fast-acting-meloxicam-toward-fda-submission-following-successful-phase-iii-trials 2025-05-09T01:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/2b329d917813fbc8/hilo-secures-42-million-series-b-funding-to-revolutionize-blood-pressure-monitoring 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/971e96f15d307ed4/fda-commissioner-signals-shift-in-covid-19-booster-strategy-requiring-stronger-clinical-evidence 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/498b959750a436ea/novel-myh9-gene-variant-identified-in-chinese-child-with-rare-hereditary-thrombocytopenia 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5f24fa92a93690f6/neurofibromatosis-type-1-with-plexiform-neurofibromas-diagnosis-epidemiology-and-clinical-manifestations 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5f3aaef1f2cf3c3/novel-contact-force-sensing-pulsed-field-ablation-catheter-shows-promise-in-paroxysmal-af-treatment 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/baf3767ae4bec58d/pharma-leadership-shuffle-key-executive-moves-in-early-2025-reshape-industry-landscape 2025-05-08T23:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/7c1e264605f37990/hyperuricemia-pipeline-shows-promise-with-15-emerging-therapies-in-development 2025-05-08T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2c88a055d3c3a06/hepatitis-d-pipeline-shows-strong-progress-with-multiple-fda-breakthrough-designations-and-promising-phase-3-results 2025-05-08T22:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/b456eb610b4e9e45/lupus-nephritis-market-expected-to-grow-as-novel-therapies-enter-clinical-trials 2025-05-08T22:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/43c1df7264f5af67/fda-to-deploy-ai-assistant-across-all-centers-by-june-30-to-accelerate-scientific-reviews 2025-05-08T22:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/bd071fd0856ec0b3/adavosertib-shows-promise-in-uterine-serous-carcinoma-despite-tolerability-challenges 2025-05-08T22:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/bc7b97392230ad57/fast-forward-trial-one-week-breast-cancer-radiotherapy-proven-equally-effective-as-three-week-standard 2025-05-08T21:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/6f275be726ee2771/apimeds-pharmaceuticals-raises-13-5-million-in-ipo-for-bee-venom-based-therapy-development 2025-05-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7551b64e654b515a/signatera-ctdna-test-predicts-recurrence-risk-in-high-risk-breast-cancer-patients-i-spy-2-trial-data-shows 2025-05-08T19:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/25e99775c68ad5e8/panitumumab-plus-folfox-significantly-improves-survival-in-ras-braf-wild-type-locally-advanced-colon-cancer 2025-05-08T19:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/54449968bf11dd90/fda-approves-miplyffa-for-niemann-pick-type-c-disease-offering-new-hope-for-rare-genetic-disorder 2025-05-08T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/9513f775151930a9/hiv-drugs-show-promising-potential-to-reduce-alzheimer-s-risk-by-up-to-13-annually 2025-05-08T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/1a4b5ce0cc2c1b7d/oryzon-genomics-secures-eur13-26-million-eu-grant-for-rare-disease-research 2025-05-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/1457e02c4505ddbb/breakthrough-wireless-device-enables-remote-activation-of-light-sensitive-drugs-for-pain-management 2025-05-08T17:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/46ed4ea18591da78/junshi-biosciences-receives-ind-approval-for-novel-bispecific-adc-targeting-egfr-and-her3 2025-05-08T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/c5cf50c3962090fc/ucla-study-advanced-mri-and-focal-therapy-revolutionize-prostate-cancer-surveillance 2025-05-08T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/1e0b910b9f9ba2be/haya-therapeutics-secures-65m-to-develop-drugs-targeting-the-dark-genome 2025-05-08T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/d9c700a77919a7ba/vintabio-showcases-high-efficiency-aav-vector-production-platform-at-asgct-2025 2025-05-08T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/68312189793e12bf/eu-regulator-confirms-suicidal-thoughts-as-rare-side-effect-of-hair-loss-drug-finasteride 2025-05-08T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/feb00808c380b5e8/alphagen-intelligence-corp-announces-195000-private-placement-for-working-capital 2025-05-08T16:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/c647e8a645f35d2e/bioarctic-expands-exidavnemab-phase-2a-trial-to-include-multiple-system-atrophy-patients 2025-05-08T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/fcc12d3132123f72/viatris-reports-q1-2025-results-pipeline-progress-despite-financial-challenges 2025-05-08T16:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/0f83b48a2414cfba/haya-therapeutics-secures-65-million-series-a-to-advance-rna-guided-medicines-targeting-the-dark-genome 2025-05-08T16:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/9b82d90e4fa61989/crenessity-shows-consistent-efficacy-across-pediatric-cah-subgroups-while-reducing-glucocorticoid-doses 2025-05-08T16:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/f098ef18d89814b2/yamo-pharmaceuticals-reports-breakthrough-phase-2-results-for-novel-autism-treatment-l1-79 2025-05-08T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/199b4824802c038b/cytophage-secures-canadian-regulatory-approval-for-novel-phage-therapy-targeting-prosthetic-joint-infections 2025-05-08T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/b3b652f11e250cab/pathos-ai-names-iker-huerga-as-ceo-to-accelerate-ai-driven-oncology-drug-development 2025-05-08T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/cadbdecdeaf83072/vivopower-advances-in-180-million-takeover-deal-with-energi-holdings-as-phase-i-due-diligence-completes 2025-05-08T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/a08d4ff32826f914/ss-innovations-to-seek-fda-approval-for-ssi-mantra-3-surgical-robotic-system 2025-05-08T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/dd145c20019b0313/nanoviricides-broad-spectrum-antiviral-nv-387-advances-to-phase-ii-trials-for-mpox-treatment 2025-05-08T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/bec2e2fa371160c8/prime-medicine-advances-gene-editing-pipeline-with-key-programs-for-cgd-wilson-s-disease-and-aatd 2025-05-08T14:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/6348bc648319dea5/vectory-therapeutics-unveils-promising-preclinical-data-for-novel-als-treatment-targeting-oxidized-phospholipids 2025-05-08T14:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/565e2bb770007a87/eminent-spine-receives-fda-510-k-clearance-for-world-s-first-3d-printed-titanium-pedicle-screw-system 2025-05-08T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/019e66dce2e212f9/viatris-reports-positive-phase-3-results-for-novel-fast-acting-meloxicam-in-acute-pain-treatment 2025-05-08T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/99ad749328fc0cf0/viatris-reports-positive-phase-3-results-for-xulane-lo-low-dose-contraceptive-patch 2025-05-08T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/7d669867447691c6/johns-hopkins-study-links-hypoglycemia-to-diabetic-retinopathy-progression-experimental-drug-shows-promise 2025-05-08T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcb5e83867235ec8/aptevo-advances-apvo711-novel-bispecific-antibody-combining-pd-l1-checkpoint-inhibition-with-cd40-immune-activation 2025-05-08T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/de779efb96f08199/nalu-reports-94-response-rate-in-largest-real-world-study-of-peripheral-nerve-stimulation-device 2025-05-08T12:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/187412f09b1b63bc/novel-antibody-plt012-targets-fat-metabolism-to-overcome-immunotherapy-resistance-in-cancer 2025-05-08T10:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/a11b7c8866b2c2f5/newlimit-secures-130m-series-b-to-advance-epigenetic-reprogramming-for-age-reversal 2025-05-08T08:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/e0d2d517dd2b8d8c/lundbeck-presents-phase-ii-data-for-amlenetug-in-multiple-system-atrophy-at-international-congress 2025-05-08T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/5d9df95226a92368/jaguar-health-advances-canalevia-ca1-field-study-for-canine-cancer-treatment-as-company-pursues-full-fda-approval 2025-05-08T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/61c392ea71186dbe/major-depressive-disorder-pipeline-advances-with-75-companies-developing-novel-therapies 2025-05-08T04:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/1f701dc479f37682/fda-s-odac-to-review-four-cancer-drugs-in-may-meeting 2025-05-08T04:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/1fbd880ca8951b56/algorae-pharmaceuticals-partners-with-peter-maccallum-cancer-centre-to-validate-ai-predicted-drug-combinations 2025-05-08T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/46ebd19e9bc17bef/rett-syndrome-pipeline-analysis-reveals-20-companies-developing-novel-therapeutics-with-gene-therapy-leading-innovation 2025-05-08T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/f2e18978bf75ee6d/new-report-reveals-promising-pipeline-for-autism-therapeutics-in-2025 2025-05-08T04:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/104e464019d9e30b/bioaffinity-technologies-secures-3-25-million-in-funding-to-advance-early-cancer-detection-technology 2025-05-08T02:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/538b00def288030e/china-s-rising-influence-in-global-drug-development-bridging-studies-transform-us-clinical-research 2025-05-08T02:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/c3109815a2ecc10c/crispr-therapeutics-casgevy-shows-commercial-progress-as-gene-therapy-pipeline-advances 2025-05-08T01:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/5f37a96db9b4d35a/fda-grants-orphan-drug-designation-to-jr-446-for-rare-neurological-disorder-mps-iiib 2025-05-08T01:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/24f85b1f4714ef00/india-s-cdsco-releases-draft-guidelines-for-biosimilars-approval-with-focus-on-advanced-analytical-methods 2025-05-08T01:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/cf42635de99e85b7/shionogi-to-acquire-japan-tobacco-s-pharma-units-for-1-1-billion 2025-05-08T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/53bd91e94579d2f5/texas-proposes-25-million-for-first-fda-approved-ibogaine-clinical-trials-for-ptsd-and-addiction 2025-05-08T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/b23b0f2486a1042e/vertex-pharmaceuticals-abandons-aav-vector-technology-amid-broader-industry-retreat-from-gene-therapy 2025-05-08T01:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/28180c2d9e922c41/atrasentan-receives-fda-accelerated-approval-for-iga-nephropathy-after-decades-long-development-journey 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b19e98536a8b4283/phase-iii-clinical-trials-reveal-advances-in-non-infectious-uveitis-treatment-options 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b571a1c50112be50/emerald-trial-data-reveals-duration-of-prior-cdk4-6-inhibitor-therapy-as-key-predictor-for-elacestrant-success-in-esr1-mutant-breast-cancer 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6b9150f78dab3a72/ema-issues-updated-guidance-on-non-mutagenic-impurity-qualification-to-reduce-animal-testing 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e29a90057ee651ff/ratio-therapeutics-to-build-65000-sq-ft-radiopharmaceutical-manufacturing-facility-in-salt-lake-city 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5d902f7b7eed0f0/federal-circuit-ruling-limits-patent-protection-for-machine-learning-applications-highlights-trade-secret-alternative 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d1b6026b3911ec2/brexit-threatens-european-medicine-supply-chain-over-45-million-patient-packs-at-risk-monthly 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a80566362ec179f/hazer-and-kbr-form-strategic-alliance-to-commercialize-low-emission-hydrogen-technology 2025-05-07T22:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/f5033205eda87dc8/myriad-genetics-riskscore-study-shows-improved-breast-cancer-screening-personalization 2025-05-07T22:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/91f79a5801338fa0/fda-partners-with-openai-to-accelerate-drug-approval-process-with-ai 2025-05-07T22:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/219d5aef7bc1cb99/bausch-lomb-secures-ce-mark-approval-for-luxlife-full-range-of-vision-intraocular-lens-in-europe 2025-05-07T19:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/ab4d767b15a643f6/ema-suspends-valneva-s-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-07T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/548ec68a02757dcc/ribbon-bio-strengthens-commercial-leadership-with-jeff-fitzgerald-appointment-as-global-sales-head-amid-mirosynthtm-dna-launch 2025-05-07T17:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/22c64e70611e3874/pasithea-therapeutics-raises-6-3-million-to-advance-mek-inhibitor-for-neurofibromatosis-type-1 2025-05-07T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9f38ff0e4e3cfd34/dcgi-launches-investigation-into-58-alleged-illegal-clinical-trials-at-vs-hospital-following-supreme-court-intervention 2025-05-07T16:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/6401063a0f6b8b0d/natera-s-prospera-heart-test-with-dqs-shows-superior-performance-in-detecting-transplant-rejection 2025-05-07T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/595d8a289454bccc/ribbon-bio-launches-mirosynthtm-dna-platform-to-advance-complex-synthetic-dna-production 2025-05-07T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/82fd130e5dacd915/gates-foundation-awards-evotec-2-5m-grant-to-advance-next-generation-tuberculosis-treatments 2025-05-07T16:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/079f226ad92cf194/tuhura-biosciences-initiates-phase-1b-2a-trial-of-ifx-hu2-0-for-deep-seated-merkel-cell-carcinoma 2025-05-07T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/0ca807cc43693c64/immunewalk-s-iw-601-shows-positive-phase-1-results-in-novel-monocyte-targeting-approach-for-inflammatory-diseases 2025-05-07T13:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/c60444b090c7f267/vigil-neuroscience-advances-dual-trem2-programs-with-promising-results-for-neurodegenerative-diseases 2025-05-07T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/4d2f3f9355bf275c/shionogi-receives-regulatory-clearance-for-torii-pharmaceutical-acquisition-tender-offer-proceeds 2025-05-07T13:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/e1c3903bf5560ffd/arkbio-s-ak3280-shows-promising-results-in-phase-ii-ipf-trial-with-significant-lung-function-improvement 2025-05-07T13:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/5e54c735eb1d1963/isarna-s-isth0036-shows-promise-in-reducing-retinal-fibrosis-in-phase-2-better-trial 2025-05-07T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/b055c929d17ba4b1/nefecon-receives-full-nmpa-approval-for-iga-nephropathy-treatment-in-china-removing-proteinuria-restrictions 2025-05-07T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/a261f634a5f353d9/corvista-health-validates-non-invasive-pulmonary-hypertension-diagnostic-system-in-major-clinical-study 2025-05-07T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/705f38e0a24c91bc/european-feder-grant-awarded-to-leo-cancer-care-and-centre-leon-berard-for-upright-radiation-therapy-innovation 2025-05-07T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/e9179dfa51e63a24/breakthrough-discovery-pla2g15-identified-as-novel-target-for-neurometabolic-disorders 2025-05-07T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/219ba0f7d2d67e53/aboleris-pharma-initiates-first-in-human-trial-of-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis 2025-05-07T10:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/601679cf93e3bb5f/breakthrough-in-primary-sclerosing-cholangitis-dr-falk-pharma-s-norucholic-acid-shows-positive-phase-3-results 2025-05-07T10:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/e413948c7172eafc/bulevirtide-shows-durable-response-in-chronic-hepatitis-delta-virus-after-treatment-cessation 2025-05-07T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/76dc045a1dfe0376/astraveus-partners-with-necstgen-to-revolutionize-car-t-manufacturing-with-microfluidic-technology 2025-05-07T10:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/6c960c08db81071e/chop-researchers-propose-alk-inhibitors-as-new-standard-for-hereditary-neuroblastoma 2025-05-07T10:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/57638b882eb4bb3a/gemvax-s-gv1001-receives-fda-fast-track-designation-and-korean-therapeutic-use-approval-for-progressive-supranuclear-palsy 2025-05-07T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/c8cf0240703d1f04/marea-s-mar-001-shows-promising-lipid-lowering-results-in-phase-2a-cardiovascular-study 2025-05-07T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/62219d8acebe5943/markel-launches-global-clinical-trials-insurance-solution-to-accelerate-research-timelines 2025-05-07T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/f6a3876c55ec84db/fastwave-medical-receives-irb-approval-for-novel-coronary-laser-intravascular-lithotripsy-system 2025-05-07T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/08384e947bc0afd8/shingles-vaccine-reduces-cardiovascular-risk-by-23-for-up-to-eight-years-study-finds 2025-05-07T07:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/8521cb9d40991a05/beacon-therapeutics-reports-promising-phase-2-data-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-05-07T07:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/70d3a093cfb844be/vinay-prasad-s-appointment-to-lead-fda-s-cber-signals-potential-shift-in-regulatory-standards 2025-05-07T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb5e31856bb0ef61/roche-launches-elecsys-pro-c3-test-for-precise-liver-fibrosis-assessment-in-masld-patients 2025-05-07T07:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/a1d02c7fc8a703ea/genenta-science-partners-with-anemocyte-to-advance-cell-based-cancer-therapy-manufacturing 2025-05-07T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/bbef53b4166cceb6/annexon-to-present-promising-data-on-anx007-s-neuroprotective-effects-in-geographic-atrophy-at-major-ophthalmology-conferences 2025-05-07T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/79049fc8b919d35e/e-therapeutics-etx-312-shows-promise-as-disease-modifying-mash-treatment-in-preclinical-studies 2025-05-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dd2e430172cc32f0/koala-health-raises-20-million-series-b-to-transform-pet-medication-delivery-platform 2025-05-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8eebad308dc65f0f/viverita-therapeutics-partners-with-boehringer-ingelheim-to-discover-novel-cancer-targets-using-in-vivo-crispr-platform 2025-05-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/68eae2ce3e561f06/aav-vector-production-challenges-drive-innovation-in-gene-therapy-manufacturing 2025-05-07T04:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/73706b1cee435139/multiple-system-atrophy-pipeline-shows-promise-with-22-therapies-in-development-as-fda-grants-fast-track-designations 2025-05-07T04:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/08ac7b9e1fa83cde/bioaegis-therapeutics-advances-global-phase-2b-trial-of-gelsolin-therapy-for-ards-treatment 2025-05-07T04:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/de12e8baaec837f6/mana-bio-unveils-ai-driven-advances-in-rna-delivery-at-asgct-2025 2025-05-07T04:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d7bbb2b66647f45/cardiothoracic-surgeon-emphasizes-human-resources-as-key-to-ai-driven-cardiovascular-care-transformation 2025-05-07T02:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/5ec455bcf92d5579/virion-therapeutics-vron-0200-shows-rapid-hbsag-declines-in-phase-1b-hepatitis-b-functional-cure-trial 2025-05-07T02:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f1be32e723a31f1/clinuvel-advances-phase-iii-trial-for-vitiligo-treatment-with-scenesse-r-recruiting-over-200-patients 2025-05-07T01:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/4c598d2d387c84f0/recludix-unveils-first-in-class-btk-sh2-domain-inhibitor-with-superior-selectivity-for-chronic-spontaneous-urticaria 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b2338365c0478f6/rapamycin-shows-promise-as-anti-aging-drug-matching-benefits-of-calorie-restriction-in-comprehensive-study 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4bb999211c46ad3e/vagus-nerve-stimulation-achieves-100-ptsd-diagnosis-loss-in-phase-1-trial 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/488abe3601393587/targeted-radiopharmaceuticals-summit-returns-to-europe-and-us-as-industry-momentum-builds 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/60752f392936bad2/zyus-life-sciences-secures-1-37-million-in-funding-for-cannabinoid-based-pain-management-research 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/23ace66b7c5d7996/fda-advisory-committee-discusses-columvi-combination-for-relapsed-or-refractory-dlbcl 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0e8f8f9b080c7a5/indian-origin-scientists-develop-weekly-injectable-for-parkinson-s-disease-treatment 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7a795ef6874724c6/medicare-beneficiaries-under-65-without-supplemental-coverage-face-significant-care-barriers 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e9dac00e82d21f99/molecular-testing-advances-personalized-treatment-strategies-in-ovarian-cancer 2025-05-06T23:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/b8a6ebde01c5cd3e/vasomune-to-present-late-breaking-data-on-av-001-s-protective-effects-against-covid-19-at-ats-conference 2025-05-06T23:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/3df5d2e9bcfa4d79/fda-expands-unannounced-inspections-at-foreign-manufacturing-facilities-to-level-global-oversight 2025-05-06T22:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/0255e5416f25d43b/molecular-profiling-reduces-radiotherapy-need-in-early-stage-endometrial-cancer 2025-05-06T22:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/7037f68afdee84e3/brightheart-secures-third-fda-clearance-for-ai-powered-fetal-heart-ultrasound-technology 2025-05-06T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/b3f2c1cc843266ca/jazz-pharmaceuticals-reports-strong-q1-2025-performance-with-898-million-in-revenue-advances-pipeline-with-zepzelca-snda-submission 2025-05-06T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/f1a1c7d7220dae04/agc-biologics-and-novelty-nobility-form-strategic-partnership-for-bispecific-antibody-development 2025-05-06T22:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/8445619a861d0be4/deerfield-management-raises-over-600m-for-third-biotech-innovation-fund 2025-05-06T19:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/f29889cd3db4f5df/elekta-unity-mr-linac-preserves-sexual-function-in-men-with-prostate-cancer-clinical-trial-shows 2025-05-06T19:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/8fdb17cb3cae2327/fda-approves-hemiclor-first-low-dose-chlorthalidone-tablet-for-hypertension-management 2025-05-06T19:38:11+00:00 hourly 0.9 https://trial.medpath.com/news/a1b78d66bc14e549/avadel-wins-federal-circuit-appeal-path-cleared-for-lumryz-development-in-idiopathic-hypersomnia 2025-05-06T19:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/7d24160ffcdcb95f/adnoc-s-eur12-billion-covestro-acquisition-faces-eu-foreign-subsidy-investigation 2025-05-06T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/958def77c7699967/zivo-bioscience-partners-with-global-animal-health-leader-to-advance-algal-derived-immune-boosters-for-poultry-disease-prevention 2025-05-06T17:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/66e35df0c3a26e13/tpg-acquires-35-stake-in-schott-poonawalla-for-300-million-strengthening-drug-delivery-innovation 2025-05-06T17:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/08594fae97eec957/24-companies-advancing-hidradenitis-suppurativa-treatment-pipeline-with-novel-therapies 2025-05-06T16:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/8ccb925036959018/boehringer-ingelheim-launches-phase-ii-trial-of-first-in-class-oral-treatment-for-geographic-atrophy 2025-05-06T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/0f3933103a39c8c8/priothera-appoints-dr-jens-hasskarl-as-chief-medical-officer-to-lead-phase-3-trial-of-mocravimod-for-acute-myeloid-leukemia 2025-05-06T16:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/c78c2b48051a3b5a/fremanezumab-shows-dual-efficacy-in-treating-both-migraine-and-depression-in-landmark-trial 2025-05-06T16:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/79a69337360209bd/india-s-dtab-streamlines-drug-trial-approvals-notification-system-introduced-timelines-halved 2025-05-06T16:37:33+00:00 hourly 0.9 https://trial.medpath.com/news/c824708ad8bf29f5/fda-clears-ind-for-ideaya-s-novel-dll3-targeting-antibody-drug-conjugate-ide849-for-solid-tumors 2025-05-06T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/552aac88f256bae9/sunshine-biopharma-launches-generic-lurasidone-for-schizophrenia-in-canadian-market 2025-05-06T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/c95de1f98f118d13/clario-strengthens-neuroscience-clinical-trial-capabilities-with-acquisition-of-wcg-s-ecoa-business 2025-05-06T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/47461be31a6f9d6d/actinium-enrolls-first-patient-in-groundbreaking-iomab-act-car-t-conditioning-trial 2025-05-06T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/6c9df5c925ec0efb/fda-approves-first-oral-glp-1-for-weight-management-as-q2-2025-brings-major-endocrinology-advances 2025-05-06T15:00:05+00:00 hourly 0.9 https://trial.medpath.com/news/1fcbc0a5262e4f0d/paradigm-therapeutics-secures-12-5m-investment-to-advance-novel-epidermolysis-bullosa-treatment 2025-05-06T14:52:24+00:00 hourly 0.9 https://trial.medpath.com/news/6c10e5cd456e64c4/zetagen-therapeutics-completes-enrollment-in-phase-2a-trial-for-novel-metastatic-breast-cancer-bone-lesion-treatment 2025-05-06T14:38:38+00:00 hourly 0.9 https://trial.medpath.com/news/af3f1c6a2bac7a33/heron-therapeutics-settles-patent-litigation-with-mylan-for-cinvanti-and-aponvie 2025-05-06T14:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/1871ce0303cfbb27/eli-lilly-and-alchemab-forge-415m-partnership-for-novel-als-antibody-therapy 2025-05-06T14:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/a921c62f53cd0a26/verona-pharma-to-present-comprehensive-analyses-of-ohtuvayre-in-copd-at-ats-2025 2025-05-06T13:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/f197a5ac4175f7c4/paradigm-shift-in-c3g-treatment-new-clinical-criteria-for-therapy-escalation-and-emerging-complement-inhibitors 2025-05-06T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/02b333bce0d990ba/livekidney-initiates-phase-i-iia-trial-of-novel-cell-therapy-lk-sc001-for-lupus-nephritis 2025-05-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/2e178eef710fcbd7/safe-life-expands-european-aed-market-presence-through-swiss-acquisition-of-resqshock 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/92bf6d44d03deb03/rapidpulse-initiates-patient-enrollment-in-pivotal-ide-study-for-novel-ischemic-stroke-treatment 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d046141c5f76ccd6/khondrion-secures-eur5-million-government-credit-to-advance-phase-3-trial-for-rare-mitochondrial-disease 2025-05-06T10:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/2ccad0c9e238ebc4/crispr-based-immunotherapy-achieves-complete-remission-in-terminal-colon-cancer-patient 2025-05-06T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/0755edc4b37d23e1/blocking-nitrosylation-a-breakthrough-strategy-for-treating-aggressive-nras-melanoma 2025-05-06T10:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/5f649f73b708e88c/fda-grants-fast-track-designation-to-givinostat-for-polycythemia-vera-treatment 2025-05-06T10:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/e0ba21a0e6c0efb6/shilpa-medicare-s-bengaluru-facility-receives-ema-gmp-certification-for-advanced-drug-delivery-systems 2025-05-06T10:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/485aeac977dd456d/biofrontera-s-ameluz-secures-patent-extension-to-2043-targets-5-7b-acne-market 2025-05-06T10:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/42d1221e26ba93d1/novaremed-completes-enrollment-in-nih-sponsored-phase-2b-trial-of-non-opioid-nrd-e1-for-diabetic-neuropathy-pain 2025-05-06T10:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/6c8ee2010cfaef84/hovione-and-firstgene-partner-to-develop-novel-gene-therapy-for-liver-cancer 2025-05-06T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/1b2d6dc6082a7dd2/viralgen-and-trogenix-partner-to-accelerate-aav-gene-therapy-for-glioblastoma 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9b0dcc995e3a46f5/dianthus-therapeutics-completes-enrollment-in-phase-2-magic-trial-for-generalized-myasthenia-gravis-treatment 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/31cfaf3b10134029/datavant-and-boehringer-ingelheim-expand-real-world-evidence-partnership-across-75-clinical-trials 2025-05-06T08:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/187f33490ca1978d/safeheal-secures-eur35-million-in-series-c-funding-to-advance-colovac-device-for-colorectal-surgery 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/f060a44385ec87ee/catheter-precision-acquires-cardionomic-s-heart-failure-technology-for-novel-neuromodulation-therapy 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/22b983d9e37280cb/vertex-pharmaceuticals-reports-strong-q1-2025-results-with-8-revenue-growth-projection-amid-pipeline-advancements 2025-05-06T07:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/39ddc81d74f72f8e/transpire-bio-expands-r-d-and-manufacturing-footprint-in-florida-to-support-inhaled-therapeutics-pipeline 2025-05-06T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ba3a3ac6e5c6f407/route-92-medical-wins-patent-litigation-settlement-q-apel-permanently-removes-competing-neurovascular-product 2025-05-06T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e37f1679ab5dc0c/novavax-and-takeda-strengthen-partnership-with-improved-terms-for-covid-19-vaccine-in-japan 2025-05-06T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/3204469e5567c665/fda-will-ask-outside-experts-to-review-capricor-s-therapy-for-duchenne-muscular-dystrophy 2025-05-06T05:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/81ca83b4a07b620b/renovorx-secures-new-u-s-patent-for-tamp-therapy-platform-strengthening-ip-portfolio-for-targeted-cancer-treatment 2025-05-06T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/33da49da06407995/fda-approves-ide-for-ecm-therapeutics-novel-hydrogel-treatment-for-anorectal-fistulas 2025-05-06T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ab1b458a9155649/ge-healthcare-s-aurora-spect-ct-and-clarify-dl-receive-fda-clearance-advancing-nuclear-medicine-imaging 2025-05-06T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/bd2687f128668fea/fda-approves-ritedose-s-albuterol-sulfate-inhalation-solution-amid-national-shortage 2025-05-06T04:40:26+00:00 hourly 0.9 https://trial.medpath.com/news/8bc5f2d1460d1d32/fangzhou-expands-access-to-breakthrough-leukemia-treatment-with-ponatinib-launch-in-china 2025-05-06T04:40:20+00:00 hourly 0.9 https://trial.medpath.com/news/b6ecd4a2cae2ed17/beijing-tide-s-first-in-class-at2r-antagonist-trd205-enters-phase-ii-trials-for-chronic-post-surgical-pain 2025-05-06T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/7f708130be7fb4fb/who-approves-naxtarubicin-as-international-generic-name-for-moleculin-s-cancer-drug-annamycin 2025-05-06T04:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/689ec0f8227f69a8/ptc518-shows-promise-in-huntington-s-disease-phase-2-trial-meets-primary-endpoint 2025-05-06T04:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/3512932a1dfb02fa/trump-administration-s-clinical-trial-system-shutdown-shocks-medical-research-community 2025-05-06T04:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/ad12e8f08c34fd53/daridorexant-shows-promising-results-in-improving-night-to-day-transition-for-insomnia-patients 2025-05-06T04:38:36+00:00 hourly 0.9 https://trial.medpath.com/news/70e23ae6838e9341/innovent-s-efdamrofusp-alfa-shows-promising-results-for-neovascular-amd-with-extended-dosing-potential 2025-05-06T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/1aa11918a2688f8e/jnj-1900-shows-promise-in-phase-1-trial-for-advanced-pancreatic-cancer 2025-05-06T04:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/d6fda6b48060263f/scribe-therapeutics-to-present-novel-crispr-based-gene-therapy-data-for-duchenne-muscular-dystrophy-at-asgct-2025 2025-05-06T04:36:43+00:00 hourly 0.9 https://trial.medpath.com/news/a7f568796d26fe76/theralase-s-light-activated-ruvidar-shows-promising-results-in-bcg-unresponsive-bladder-cancer-clinical-trial 2025-05-06T04:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/24e8f1db819db001/car-t-cell-therapies-drive-growth-in-adult-t-cell-leukemia-lymphoma-market-despite-access-challenges 2025-05-06T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d11a070f8819caf/integra-therapeutics-and-factor-bioscience-showcase-advanced-gene-editing-technologies-for-car-t-cell-therapies-at-asgct-2025 2025-05-06T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/fcfbc40a699d2117/genprex-secures-exclusive-license-for-reqorsa-gene-therapy-in-glioblastoma-treatment 2025-05-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/21e70e34393bedef/lundbeck-partners-with-dcai-to-accelerate-brain-disorder-drug-discovery-using-gefion-ai-supercomputer 2025-05-06T02:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb67fc3d62aca4bf/inbrain-neuroelectronics-secures-eur4-million-grant-to-advance-graphene-based-brain-computer-interface-technology 2025-05-06T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3bb2055be74c7c7b/repose-study-confirms-real-world-efficacy-of-higher-dose-onabotulinumtoxina-for-chronic-migraine 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/96d949cf1433619d/lilly-partners-with-creyon-bio-in-1b-deal-to-develop-ai-designed-rna-therapies 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/45db5003c359db4f/dynamic-biomarkers-show-promise-for-predicting-immune-checkpoint-inhibitor-response-in-cancer-patients 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/60fd640e78e0d195/sk-bioscience-selected-for-korea-s-national-avian-influenza-vaccine-development-program 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d1c6e32f72f3c149/ousia-pharma-secures-seed-financing-from-omega-funds-to-develop-novel-obesity-treatment-targeting-nmda-receptors 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f8553cadca53c31a/agendia-s-blueprint-test-shows-promise-in-identifying-chemotherapy-responsive-breast-cancer-subtypes 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ba16fcaa27cd5d41/cbd-life-sciences-expands-global-footprint-with-strategic-manufacturing-partnerships-in-colombia-and-u-s 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f972cdf7e687accd/endospan-s-nexus-aortic-arch-stent-graft-shows-promising-30-day-results-in-fda-triomphe-trial 2025-05-05T20:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/c24097c5714e0904/kane-biotech-secures-2-2-million-through-private-placement-and-insider-loan-to-advance-biofilm-disrupting-wound-care-technology 2025-05-05T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/65a9d6134f8575d0/new-jersey-transforms-cancer-care-landscape-with-first-freestanding-cancer-hospital 2025-05-05T15:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8a651c34969c9ad/ferring-s-iris-study-demonstrates-improved-ivf-outcomes-with-individualized-follitropin-delta-dosing-in-indian-patients 2025-05-05T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2da70ce558595d93/cannabix-technologies-secures-nhtsa-approval-and-manufacturing-partnership-for-breathlogix-alcohol-screening-device 2025-05-05T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/13f197a5f19f326f/pharmacy-industry-fellowships-a-critical-pathway-for-pharmd-graduates-career-development 2025-05-05T14:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/040cc039359f6a87/ascendis-pharma-presents-long-term-data-on-rare-endocrine-disease-therapies-at-major-medical-conferences 2025-05-05T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/0266dc9dee113d18/regeneration-biomedical-reports-promising-phase-1-results-for-direct-brain-injection-of-stem-cells-in-alzheimer-s-disease 2025-05-05T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/d11c63516ea9bc02/texas-girl-to-make-medical-history-with-first-ever-treatment-for-rare-nars1-genetic-disorder 2025-05-05T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/598230c46ee760d9/new-phase-1-trial-combines-tagraxofusp-and-pacritinib-for-treatment-resistant-myelofibrosis 2025-05-05T09:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/77a681739bf6fcc1/autonomix-medical-reports-significant-pain-reduction-in-pancreatic-cancer-patients-with-novel-nerve-ablation-technique 2025-05-05T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/bed7074403e447f4/ontada-presents-14-real-world-evidence-studies-at-ispor-2025-to-advance-cancer-care-research 2025-05-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/74fcc76ed598ed4c/dual-target-alzheimer-s-vaccine-duvax-receives-3-million-nih-grant-for-phase-1-trials 2025-05-05T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd19e605ff996d58/palatin-s-pl9588-shows-promise-as-dual-action-glaucoma-therapy-with-neuroprotective-effects 2025-05-05T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fb6b105347f12369/janux-therapeutics-advances-janx007-to-phase-1b-trials-for-prostate-cancer-with-promising-survival-data 2025-05-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/f70a68ab7f26b7bb/targeted-therapies-transform-biliary-tract-cancer-treatment-as-her2-directed-agents-gain-fda-approval 2025-05-05T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/8ceb62728edeff30/brain-cancer-canada-awards-170k-for-two-glioblastoma-research-projects-targeting-treatment-resistance 2025-05-05T05:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/31dd8669d64111c2/bionxt-solutions-secures-eurasian-patent-approval-for-sublingual-ms-treatment-technology 2025-05-05T03:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/109259ff7bb0b28b/biomed-industries-reports-phase-2-success-for-oral-obesity-drug-na-931-at-ada-2025 2025-05-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ccd1488f97a347db/crispr-gene-editing-therapy-shows-promise-in-first-human-trial-for-advanced-gi-cancers 2025-05-04T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/966b7b1612d94ee3/fda-to-slash-drug-approval-times-by-half-with-new-streamlined-procedures 2025-05-04T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/75469ede2ab0523c/fda-expands-quikclot-control-hemostatic-device-indications-to-all-bleeding-grades 2025-05-04T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/331109dc8ba72e56/fda-clears-ind-for-nutshell-therapeutics-novel-p53-y220c-reactivator-nts071 2025-05-04T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/a446d5a22d3f7b4e/home-administration-of-long-acting-hiv-injectable-therapy-proves-safe-and-effective-as-clinic-treatment 2025-05-04T04:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/842eaf66f96a1f65/io-biotech-s-novel-immune-modulatory-cancer-vaccine-shows-promise-in-phase-3-trials 2025-05-04T04:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/1092b12222d568c3/combination-therapy-shows-promise-for-hepatitis-b-functional-cure-with-100-sustained-seroconversion-in-preclinical-study 2025-05-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/c278f2d7be5a2188/district-court-dismisses-united-therapeutics-dispute-against-liquidia-in-patent-litigation 2025-05-03T20:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/f16e1f9bd4790800/university-of-hyderabad-and-krismo-biosciences-partner-to-develop-novel-therapies-for-inflammatory-diseases-and-viral-infections 2025-05-03T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/9600ad057da152a8/tae-life-sciences-and-ohio-state-university-partner-to-advance-boron-neutron-capture-therapy-for-cancer-treatment 2025-05-03T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/495faf71b3f9066e/complicated-urinary-tract-infection-pipeline-shows-robust-development-with-12-companies-advancing-novel-therapies 2025-05-03T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/182379f0d42d2985/risankizumab-and-guselkumab-show-comparable-efficacy-in-real-world-psoriasis-treatment-over-one-year 2025-05-03T16:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/df4915c08720dd4f/summit-therapeutics-ivonescimab-shows-promising-results-in-phase-3-nsclc-trial 2025-05-03T13:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/32d7b8f492bfd224/tissuecypher-test-shows-promise-in-identifying-barrett-s-esophagus-patients-at-risk-for-esophageal-cancer 2025-05-03T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/92a4bb5c3b735b01/pliant-therapeutics-cuts-workforce-by-45-following-termination-of-idiopathic-pulmonary-fibrosis-trial 2025-05-03T13:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/b606e3afbb900d8e/novel-smart-capsule-technology-could-revolutionize-multi-medication-regimens 2025-05-03T11:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/04d53bd855f64f41/fda-approved-pinworm-drug-shows-promise-against-deadly-merkel-cell-carcinoma 2025-05-03T10:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/78e19fb58f9fe1fd/breakthrough-universal-antivenom-developed-using-blood-of-man-bitten-200-times 2025-05-03T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c78958af98fabd4/zucara-therapeutics-secures-25m-series-b-funding-to-advance-first-in-class-hypoglycemia-prevention-therapy 2025-05-03T07:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/01ca152e34b3afb8/faricimab-shows-superior-fluid-reduction-and-sustained-efficacy-in-wet-amd-through-3-year-data 2025-05-03T07:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/7b2edd6af6de5cef/evolving-treatment-landscape-for-egfr-mutant-nsclc-managing-resistance-and-optimizing-therapy-sequence 2025-05-03T04:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/7c477d38012f60cc/immuneoncia-therapeutics-raises-24m-in-successful-kosdaq-ipo-for-cancer-drug-development 2025-05-03T01:35:57+00:00 hourly 0.9 https://trial.medpath.com/news/012274d0427438ee/court-dismisses-united-therapeutics-challenge-against-liquidia-s-yutrepia-clearing-path-for-may-launch 2025-05-03T01:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/16171e616bb21c09/edwards-lifesciences-receives-fda-approval-for-tavr-therapy-in-asymptomatic-severe-aortic-stenosis 2025-05-02T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/cf65b6ed826825cc/abbott-partners-with-epic-to-integrate-freestyle-libre-cgm-data-into-electronic-health-records 2025-05-02T20:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/8222d55d2b729920/thermo-fisher-scientific-partners-with-roosterbio-to-accelerate-cell-and-exosome-therapy-development 2025-05-02T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/97a44d5a20db1d10/genmab-plans-fda-submission-for-epcoritamab-combination-therapy-in-relapsed-follicular-lymphoma 2025-05-02T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/adad32de7b1c5f00/turn-therapeutics-achieves-breakthrough-in-room-temperature-vaccine-stability 2025-05-02T19:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/a767e47fa385a06a/study-confirms-clinical-trial-results-accurately-predict-real-world-benefits-of-prostate-cancer-therapies 2025-05-02T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/18f30c890015f868/amgen-s-stelara-biosimilar-generates-150-million-in-first-quarter-highlighting-biosimilar-strategy-success 2025-05-02T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/b85fc06aa469d1bf/sohm-recruits-car-t-expert-dr-leonardo-mirandola-to-advance-novel-gene-editing-platform-toward-clinical-trials 2025-05-02T16:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/c9abd74d9e2a8555/alembic-pharmaceuticals-receives-fda-approval-for-generic-ticagrelor-tablets-to-reduce-cardiovascular-risks 2025-05-02T16:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/c99bd1171f7f9d2d/breakthrough-drug-trial-shows-life-changing-results-for-children-with-dravet-syndrome 2025-05-02T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/3c369e6eabe1380b/novel-in-vivo-cd19-car-t-therapy-achieves-complete-remission-in-aggressive-dlbcl-without-lymphodepletion 2025-05-02T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2a1be65f7b1dee19/gsk-to-present-groundbreaking-respiratory-medicine-data-at-ats-2025-international-congress 2025-05-02T13:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/1bff64e6cb5645b8/fda-denies-cytosorbents-de-novo-request-for-drugsorb-atr-blood-purification-device 2025-05-02T13:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/b062d8399ef986cc/first-patient-dosed-in-phase-1-trial-of-kh658-gene-therapy-for-wet-amd 2025-05-02T13:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/a7866ab8039a77ae/cour-pharma-initiates-cnp-103-clinical-trial-for-newly-diagnosed-type-1-diabetes-patients 2025-05-02T13:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/adb44ada3a1cf76c/novo-nordisk-s-weight-loss-drug-wegovy-now-available-in-qatar-through-ebn-sina-medical-partnership 2025-05-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/9a3242ac08ad0ef8/nhs-explores-pharmacy-based-weight-loss-injection-program-to-expand-access-at-prescription-prices 2025-05-02T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/7ab9534ff0647d2f/anavex-completes-enrollment-in-phase-2-trial-of-anavex-r-3-71-for-schizophrenia-treatment 2025-05-02T10:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/5c8bf65fa4a12fbb/shashvi-remedies-secures-rs-10-lakh-grant-for-breakthrough-breast-cancer-treatment-patent 2025-05-02T10:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/b104c2777b101bdc/iq-ai-seeks-fda-breakthrough-therapy-designation-for-promising-glioblastoma-treatment 2025-05-02T10:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/14162ef6e2ca2979/metformin-shows-promise-in-reducing-knee-osteoarthritis-pain-in-overweight-patients 2025-05-02T10:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/2a74aaf177b8459c/global-study-reveals-significant-gender-disparities-in-health-outcomes 2025-05-02T10:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/12f7123aba40bbd2/astrazeneca-s-breztri-shows-significant-improvement-in-phase-iii-asthma-trials 2025-05-02T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/4e01b17483ad16d3/amgen-reports-strong-global-demand-in-q1-2025-bolstering-long-term-growth-outlook 2025-05-02T07:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/f714ac0479451ef8/biogen-advances-leqembi-treatment-with-subcutaneous-formulation-for-alzheimer-s-disease 2025-05-02T07:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/e0afe78c930561a9/endoform-natural-demonstrates-significant-healing-advantage-for-venous-leg-ulcers-in-large-real-world-study 2025-05-02T05:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/d650a82370208b62/aventus-thrombectomy-system-shows-promise-for-pulmonary-embolism-treatment-in-pivotal-trial 2025-05-02T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/63c1530073c59017/histoindex-secures-9-million-investment-to-advance-ai-powered-liver-disease-diagnostics 2025-05-02T04:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/1b17767ed37f2066/real-world-data-emerges-as-key-solution-to-oncology-treatment-challenges 2025-05-02T04:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/469e5e535edfc6ac/study-reveals-significant-pregnancy-risks-for-minority-women-with-cancer 2025-05-02T02:39:41+00:00 hourly 0.9 https://trial.medpath.com/news/0419ce114ef45099/vibegron-shows-sustained-long-term-safety-and-efficacy-for-men-with-oab-and-bph 2025-05-02T01:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/097d16c245fb5fcb/novel-nucleus-pulposus-allograft-shows-promise-for-chronic-back-pain-treatment 2025-05-02T01:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/f4bac0049a42d79a/fda-clears-ocumet-beacon-a-novel-non-invasive-retinal-imaging-device 2025-05-02T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/fe1234a711c9f575/repare-therapeutics-licenses-discovery-platforms-to-dcx-biotherapeutics-in-strategic-refocus-on-clinical-pipeline 2025-05-02T01:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/a1c2a80e165bdb94/astrazeneca-advances-azd0780-cholesterol-lowering-drug-through-phase-ii-and-iii-clinical-trials 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fa948e04eabce96c/foresee-pharmaceuticals-launches-phase-2-trial-of-mirivadelgat-for-pulmonary-hypertension-associated-with-interstitial-lung-disease 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d5b20894698a7518/moderna-s-combination-mrna-vaccine-for-covid-19-and-influenza-shows-promise-in-phase-3-trial 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1a8e5116a2b54238/bluenalu-expands-partnership-with-nomadfoods-to-commercialise-cell-based-products-in-uk-europe 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7c4e0162f4164ae/gene-therapy-shows-promising-results-in-children-with-rare-immune-disorder-lad-i 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/34321859ca9d11f8/alk-and-ars-pharma-partner-to-co-promote-neffy-first-needle-free-epinephrine-nasal-spray-for-anaphylaxis 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f5ba98688109147/single-antiplatelet-therapy-shows-superior-safety-profile-over-dual-therapy-after-tavr 2025-05-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c906ed60eb38d0b6/dupilumab-shows-sustained-lung-function-improvements-in-copd-patients-with-type-2-inflammation 2025-05-01T23:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/8cf17a7a02dfd6bb/strides-pharma-secures-usfda-approval-for-celecoxib-capsules-targeting-116m-market 2025-05-01T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/db4ba2c645443234/new-bone-marrow-test-could-double-survival-rates-for-acute-myeloid-leukemia-patients 2025-05-01T20:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/7483ea35d1d8f69d/cnd-life-sciences-secures-13-5m-series-a-funding-to-advance-skin-based-neurodegenerative-disease-diagnostics 2025-05-01T20:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/9122421df4ab87e3/bayer-advances-liver-cancer-treatment-with-first-in-human-trial-of-novel-targeted-alpha-therapy 2025-05-01T20:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/710caa6e4dbed9ea/magnetic-silk-microparticles-a-breakthrough-for-targeted-drug-delivery 2025-05-01T19:36:26+00:00 hourly 0.9 https://trial.medpath.com/news/4caeaecf660af224/fda-considers-new-conditional-approval-pathway-for-rare-disease-treatments 2025-05-01T19:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/edc11614ed3891e1/fda-approves-element-science-s-jewel-patch-a-revolutionary-wearable-defibrillator-for-sudden-cardiac-arrest-risk 2025-05-01T19:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/2dd3b4c87118382a/hhs-and-nih-launch-generation-gold-standard-universal-vaccine-platform-to-combat-pandemic-threats 2025-05-01T19:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/ad5bf229836dbce1/who-set-to-endorse-glp-1-weight-loss-drugs-globally-addressing-access-challenges 2025-05-01T16:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/97095faecf2be205/illumina-and-ovation-io-launch-groundbreaking-glp-1-dataset-to-transform-metabolic-disease-treatment 2025-05-01T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/e87e08c963f1c612/biotech-dimerix-lands-940m-licensing-deal-for-kidney-drug-sales-afr 2025-05-01T16:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/424430bdf4005beb/qps-india-successfully-completes-us-fda-regulatory-inspection-marking-46th-regulatory-approval 2025-05-01T16:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/21202d503ad22dbb/fda-approves-first-tavr-therapy-for-asymptomatic-severe-aortic-stenosis-patients 2025-05-01T16:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/79929a06a0e84a35/novel-bispecific-antibody-tarlatamab-shows-promise-in-relapsed-small-cell-lung-cancer 2025-05-01T16:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/ba279d50b1567ee8/armata-s-bacteriophage-therapy-shows-promising-results-in-treating-staphylococcus-aureus-bacteremia 2025-05-01T16:36:20+00:00 hourly 0.9 https://trial.medpath.com/news/bd2682d332f5c08f/us-biotech-companies-shift-clinical-trials-abroad-amid-fda-uncertainty 2025-05-01T16:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/7375d1b3ce047bd0/tempus-launches-time-precision-network-to-accelerate-phase-i-clinical-trial-enrollment 2025-05-01T16:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/ffbc613f6d1a0ce9/fda-approved-cimerli-first-interchangeable-biosimilar-for-ocular-conditions-now-available 2025-05-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/32fb5bec6c2b3bea/amicus-therapeutics-reports-15-revenue-growth-in-q1-2025-expands-portfolio-with-dmx-200-licensing-deal 2025-05-01T14:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/81d77c2430751f8e/aviadobio-completes-second-cohort-in-phase-1-2-trial-for-frontotemporal-dementia-gene-therapy 2025-05-01T13:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/b32ccb43181686bc/biosplice-initiates-phase-2-trial-of-cirtuvivint-for-advanced-soft-tissue-sarcomas 2025-05-01T13:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/48a683efc6051828/ema-grants-positive-opinion-for-orphan-drug-designation-to-nuformix-s-nxp002-for-idiopathic-pulmonary-fibrosis 2025-05-01T10:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/406dfed0a7ed9777/bimekizumab-demonstrates-sustained-three-year-efficacy-in-psoriatic-arthritis-and-axial-spondyloarthritis 2025-05-01T09:54:49+00:00 hourly 0.9 https://trial.medpath.com/news/b8419951e4dae9ce/statins-linked-to-61-reduced-cancer-mortality-in-cll-sll-patients-on-targeted-therapy 2025-05-01T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/d9ed3dd74cb8f6b2/astellas-to-present-new-izervay-data-on-geographic-atrophy-at-major-ophthalmology-congresses 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c9aea01563ce2e3/osstec-secures-ps2-5m-to-advance-3d-printed-joint-replacement-technology-to-us-market 2025-05-01T08:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/7f7f86c4501d77d8/concentra-biosciences-acquires-two-biotech-companies-in-strategic-consolidation-move 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7d4770eb8a7665d/adela-s-tissue-agnostic-mrd-test-shows-promise-for-predicting-immunotherapy-response-in-solid-tumors 2025-05-01T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d8c623bcf25b5d7/kennedy-mandates-placebo-testing-for-all-new-vaccines-potentially-impacting-fall-covid-boosters 2025-05-01T08:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/f602782074066096/tirzepatide-shows-favorable-muscle-composition-changes-in-type-2-diabetes-patients-surpass-3-trial-analysis-reveals 2025-05-01T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4bac026232cb9cec/common-cytomegalovirus-may-enhance-immunotherapy-outcomes-in-melanoma-patients-oxford-study-finds 2025-05-01T05:41:02+00:00 hourly 0.9 https://trial.medpath.com/news/211d9f4ca233ce15/lexeo-therapeutics-to-showcase-advanced-aav-manufacturing-platform-at-asgct-annual-meeting 2025-05-01T05:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8021602fa9feb82/sapience-therapeutics-to-present-phase-2-lucicebtide-data-for-glioblastoma-at-asco-2025 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/66214eab528e6cfc/haleon-partners-with-brightseed-to-leverage-ai-for-natural-bioactive-discovery-in-consumer-health 2025-05-01T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6ffec457f15b91b3/stanford-health-care-deepens-integration-of-atropos-health-s-real-world-evidence-platform-into-clinical-workflow 2025-05-01T04:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/2eb0bde08515164d/supreme-court-demands-response-on-alleged-illegal-clinical-trials-at-gujarat-hospital 2025-05-01T04:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/1e12287a68032636/puretech-s-deupirfenidone-shows-unprecedented-efficacy-in-ipf-treatment-phase-2b-results-to-be-presented-at-ats-conference 2025-05-01T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/15e3b9bda6990564/real-world-study-reveals-biomarker-status-drives-survival-and-cost-disparities-in-advanced-nsclc 2025-05-01T03:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/bf49938e5116cfe0/study-reveals-long-term-organ-damage-in-children-following-covid-19-infection 2025-05-01T03:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/7af46f3666a0023b/pl-bioscience-develops-world-s-first-artificial-human-platelet-lysate-for-cell-culture-applications 2025-05-01T03:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/471076eb55ebf96d/cancer-vaccines-emerge-as-promising-frontier-in-oncology-with-multiple-approaches-showing-clinical-success 2025-05-01T02:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/f236e6f9bd3eaada/cml-treatment-market-poised-for-significant-growth-through-2032-amid-wave-of-recent-fda-approvals 2025-05-01T01:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/ab4607579b697dcd/elite-pharmaceuticals-launches-generic-percocet-for-moderate-to-severe-pain-management 2025-05-01T01:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/72158e56345073ce/astrazeneca-advances-two-novel-obesity-treatments-in-phase-iib-trials 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2eab5d784ed191ab/s-e-bio-secures-landmark-approval-for-first-exosome-based-stroke-therapy-trial-in-korea 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dca074cb79cec71a/akari-therapeutics-appoints-mark-f-kubik-to-lead-oncology-business-development-for-novel-adc-platform 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a82b0b48debfa3cb/novartis-expands-virtual-clinical-trial-partnership-with-science-37-to-cut-r-d-costs 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4cf9e80f6c59bae/enara-bio-strengthens-leadership-team-with-key-appointments-as-company-advances-dark-antigen-t-cell-engager-pipeline 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8a369b49d5f3795c/belfast-based-amply-discovery-secures-1-75m-to-accelerate-ai-driven-drug-development-for-cancer-and-antimicrobial-resistance 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/504edebb07dc2321/astrazeneca-advances-baxdrostat-in-phase-iii-trials-for-uncontrolled-and-resistant-hypertension 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dae68e26867b4ecc/astrazeneca-initiates-phase-i-studies-of-azd2389-for-liver-fibrosis-and-nash-treatment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/acd967d6e1fc0ced/evotec-and-bristol-myers-squibb-achieve-major-milestone-in-molecular-glue-degrader-collaboration-triggering-75m-payment 2025-05-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8c4e168935f29bc/wegovy-shows-promise-in-treating-mash-a-serious-liver-disease 2025-04-30T23:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/9bdbf5c3c72925b5/ema-approves-loba-biotech-as-new-manufacturing-site-for-pegasys-restoring-european-supply 2025-04-30T22:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/b07942560c73e5de/nccn-updates-breast-cancer-and-ovarian-cancer-treatment-guidelines-with-new-maintenance-therapy-and-immunotherapy-recommendations 2025-04-30T21:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/0187b92b9b3947e6/gsk-s-zejula-shows-promising-results-in-phase-ii-mesothelioma-trial-with-27-reduction-in-disease-progression 2025-04-30T19:37:35+00:00 hourly 0.9 https://trial.medpath.com/news/a3c6af6a2dd53772/flagship-pioneering-appoints-biotech-veteran-rahul-kakkar-as-ceo-of-somatic-genomics-company-quotient-therapeutics 2025-04-30T19:37:33+00:00 hourly 0.9 https://trial.medpath.com/news/4af6da1ae2370179/fda-approves-astrazeneca-s-imfinzi-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-04-30T17:37:52+00:00 hourly 0.9 https://trial.medpath.com/news/381f14846f378cfb/novartis-acquires-regulus-therapeutics-for-800m-expanding-kidney-disease-portfolio 2025-04-30T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/40fba3b6257c744e/geovax-advances-gedeptin-gene-therapy-for-solid-tumors-with-expanded-patent-portfolio-and-promising-clinical-data 2025-04-30T16:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/354e9455df6e3e4e/er-kim-and-puma-biotechnology-partner-to-bring-nerlynx-to-eastern-europe-and-central-asia-for-her2-positive-breast-cancer-patients 2025-04-30T16:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/af46ae0739e98fff/predicta-biosciences-launches-genopredicta-a-novel-diagnostic-test-for-multiple-myeloma 2025-04-30T16:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/a7dfd777557e28d0/cytophage-launches-european-pilot-study-for-aviphage-targeting-antibiotic-free-poultry-production 2025-04-30T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/bee5d4bacbb9c71c/3p-innovation-launches-next-generation-dpi-filling-technology-promising-faster-production-of-inhalable-therapeutics 2025-04-30T16:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/1b8f50f37f9ab8ce/miniject-shows-sustained-5-year-efficacy-in-glaucoma-treatment-istar-medical-reports 2025-04-30T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/aeeff658c3c60bf6/cessatech-s-ct001-nasal-spray-achieves-primary-endpoints-in-pivotal-pediatric-pain-study 2025-04-30T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/69c77860d0e35bf9/iterum-therapeutics-secures-5-million-in-funding-to-advance-commercialization-of-novel-antibiotic-orlynvah 2025-04-30T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5d2ca149c5d9d31/metagenomic-next-generation-sequencing-demonstrates-superior-diagnostic-performance-for-severe-pneumonia-pathogen-detection 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3eda50bc387f8c25/histone-modifications-drive-tumor-associated-macrophage-polarization-in-cancer-immunotherapy 2025-04-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/162f90c8c1994e73/alnylam-concedes-defeat-in-covid-19-vaccine-patent-dispute-with-pfizer-and-biontech 2025-04-30T15:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/a6064fdf6fba473f/pangia-biotech-to-present-ai-driven-urine-based-prostate-cancer-detection-platform-at-asco-2025 2025-04-30T15:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/ef692f8c08d8c57e/big-pharma-m-a-activity-surges-as-companies-target-undervalued-biotechs-amid-market-recovery 2025-04-30T14:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6a8523a8f5ab68c/alembic-pharma-shares-surge-following-usfda-clearance-of-panelav-oncology-facility 2025-04-30T14:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/3cb5e359a38c0891/jak-inhibitor-comparison-reveals-optimized-treatment-strategies-for-myelofibrosis-patients-with-cytopenias 2025-04-30T14:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/de68dbda572dc13b/zeiss-and-boehringer-ingelheim-partner-on-ai-powered-platform-to-transform-ophthalmic-research-and-personalized-eye-care 2025-04-30T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/00e86c48a787b9cd/neurocrine-biosciences-advances-novel-muscarinic-m4-agonist-to-phase-3-trials-for-schizophrenia 2025-04-30T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/87cd9bacafe2266e/hong-kong-approves-velsipity-r-for-moderately-to-severely-active-ulcerative-colitis 2025-04-30T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/c4298a9b806567ce/honorhealth-launches-first-global-trial-of-novel-t-cell-therapy-targeting-aggressive-melanoma 2025-04-30T13:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/8cadbb8bf11d01f3/oncocyte-advances-toward-clinical-trial-for-organ-transplant-rejection-test-kit 2025-04-30T13:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/da89a30cb46cf6ee/achieve-life-sciences-files-for-fda-approval-of-cytisinicline-first-new-smoking-cessation-drug-in-nearly-20-years 2025-04-30T11:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/aef3e7ebe685d5ec/rage-inhibitor-pipeline-shows-promise-for-inflammatory-diseases-with-5-companies-advancing-novel-therapeutics 2025-04-30T11:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/52a7759b22066f45/x-chem-and-orion-pharma-expand-collaboration-to-accelerate-small-molecule-drug-discovery 2025-04-30T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a091aa64be0de69b/bold-therapeutics-presents-breakthrough-data-on-bold-100-s-neuroprotective-effects-at-aacr-2025 2025-04-30T08:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/bed12164b59f1823/lantheus-alzheimer-s-radiodiagnostic-mk-6240-achieves-pivotal-study-success-nda-filing-planned 2025-04-30T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/462b19e9eab05bfa/parp-inhibitor-niraparib-shows-breakthrough-results-in-mesothelioma-treatment 2025-04-30T07:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/9ee85792dcd05776/trump-s-first-100-days-tariffs-and-workforce-cuts-reshape-healthcare-industry 2025-04-30T07:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/256bb9ec7fc80b4a/apertura-gene-therapy-partners-with-rett-syndrome-research-trust-to-advance-blood-brain-barrier-crossing-gene-therapy-platform 2025-04-30T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f9eac79c630513d/sapient-launches-dynamiq-next-generation-multi-omics-platform-set-to-transform-drug-discovery-and-development 2025-04-30T07:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/883f7bebdd59e999/nodthera-s-nlrp3-inhibitor-nt-0796-shows-enhanced-weight-loss-when-combined-with-glp-1-therapy 2025-04-30T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/132f4b3a6e02356a/federal-court-dismisses-sanofi-s-appeal-orders-amgen-s-repatha-patent-applications-to-proceed-in-australia 2025-04-30T06:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/149e6da750a7654f/genincode-faces-fda-hurdles-in-de-novo-submission-for-cardiovascular-genetic-risk-assessment 2025-04-30T06:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/65b286ad20d59e91/fda-clears-path-for-ingenium-s-nk-cell-therapy-gengleucel-to-enter-phase-2-trials-for-mrd-aml 2025-04-30T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/408b0d69c885fba1/trisalus-life-sciences-secures-22-million-private-placement-to-advance-oncology-drug-delivery-platform 2025-04-30T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcbd9ff557260049/fruquintinib-capecitabine-combination-shows-promise-as-maintenance-therapy-for-ras-braf-wild-type-metastatic-colorectal-cancer 2025-04-30T04:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/03fb32d34b3d3044/low-lung-cancer-screening-rates-in-us-threaten-patient-outcomes-despite-proven-benefits 2025-04-30T02:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/e9b4c46a02b5f435/cinclus-pharma-advances-linaprazan-glurate-toward-phase-iii-trials-for-acid-related-diseases 2025-04-30T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7204eb50cb5035d4/dual-biopsy-approach-significantly-improves-survival-in-advanced-cancer-patients 2025-04-30T01:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/cb7955dd500a3813/sparc-shares-drop-19-following-failed-psoriasis-drug-trial 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7364b3141f3ab2c1/first-comprehensive-post-marketing-safety-comparison-reveals-differing-adverse-event-profiles-for-geographic-atrophy-treatments 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6f688223a644ce79/centivax-secures-45m-series-a-and-cepi-funding-to-advance-universal-influenza-vaccine-platform 2025-04-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0afa759208b12a9e/groundbreaking-gene-therapy-gives-new-life-to-boy-with-death-sentence-immune-disease 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/c40d54c58e471cc5/jeffs-brands-divests-u-s-e-commerce-assets-to-canadian-public-company-in-11-8-million-strategic-transaction 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/11524f43e3488d2f/fda-approves-j-j-s-akeega-for-brca-positive-metastatic-prostate-cancer 2025-04-29T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/9aca6e4e6a78b193/d3s-001-shows-breakthrough-efficacy-as-next-generation-kras-g12c-inhibitor-in-multiple-cancer-types 2025-04-29T23:57:26+00:00 hourly 0.9 https://trial.medpath.com/news/587bc17f3a6a3e27/new-study-challenges-fda-s-safety-claims-on-mifepristone-prompting-regulatory-scrutiny 2025-04-29T22:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/64d9f7b688f62cb2/gilead-to-showcase-new-data-on-liver-disease-treatments-at-easl-2025-congress 2025-04-29T22:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/23fa57dfb1c4a5d4/proofpilot-and-digital-medicine-society-partner-to-develop-digital-tools-for-opioid-use-disorder-prevention 2025-04-29T22:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/6b36c42d707e1541/rafael-holdings-completes-25-million-rights-offering-to-fund-trappsol-cyclo-phase-3-trial-for-rare-disease 2025-04-29T21:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/69c2acbf81c6e85b/novel-icam-1-targeting-car-t-cell-therapy-shows-promise-in-advanced-thyroid-cancers 2025-04-29T19:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/bb5362f9ac105100/astrazeneca-exits-neuroscience-research-to-focus-on-core-therapeutic-areas 2025-04-29T19:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/dfad8584ee0f5ffd/pharmamar-seeks-eu-fast-track-status-for-lurbinectedin-tecentriq-combination-in-extensive-stage-sclc 2025-04-29T19:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/5144aa6385d33efc/racial-and-ethnic-disparities-persist-in-pediatric-neuroblastoma-survival-despite-clinical-trial-access 2025-04-29T19:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/273297682cd65f6a/central-florida-kidney-specialists-partners-with-clintrial-research-to-advance-nephrology-clinical-trials 2025-04-29T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/462c1a73723cf757/novartis-fabhalta-poised-to-transform-treatment-landscape-for-multiple-complement-mediated-diseases 2025-04-29T17:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/e0c91e30491b6e12/astrazeneca-discontinues-phase-3-trial-of-truqap-for-metastatic-prostate-cancer 2025-04-29T16:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/1ae99e91d5f81322/johns-hopkins-medicine-joins-renovorx-s-phase-iii-pancreatic-cancer-trial-as-new-enrollment-site 2025-04-29T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/70ebd42040cca1bc/forecast-2-world-first-trial-uses-tumor-organoids-to-personalize-bowel-cancer-treatment 2025-04-29T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/3c730ebaa7f56412/zyversa-s-ic-100-shows-promise-as-disease-modifying-treatment-for-parkinson-s-disease 2025-04-29T16:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/e2e6ce7f440d1244/fda-grants-fast-track-designation-to-incyclix-bio-s-inx-315-for-ccne1-amplified-platinum-resistant-ovarian-cancer 2025-04-29T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/635ef198bf023b16/continuity-biosciences-expands-into-aesthetics-with-strategic-investment-in-3d-printed-microneedle-technology 2025-04-29T16:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/934404a1afcc7561/nanoviricides-advances-nv-387-as-potential-treatment-for-measles-amid-declining-vaccination-rates 2025-04-29T16:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/57d642f2f5cc8f63/palatin-s-pl9643-achieves-unprecedented-complete-symptom-resolution-in-dry-eye-disease-phase-3-trial 2025-04-29T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/fca4896950e0f572/breakthrough-in-diabetes-management-first-one-year-cgm-system-integrates-with-automated-insulin-delivery 2025-04-29T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/21e87d40e1ca5545/morepen-laboratories-advances-development-of-resmetirom-for-nash-treatment 2025-04-29T16:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/417291ed2b99db4e/fda-approves-shorla-oncology-s-tepylute-100mg-first-ready-to-dilute-multi-dose-thiotepa-for-breast-and-ovarian-cancer 2025-04-29T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/674016601a9ec3ab/fda-budget-cuts-linked-to-drug-approval-delays-as-small-biotech-faces-pdufa-postponement 2025-04-29T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/64106b534a3e931b/unravel-biosciences-advances-rvl-001-to-clinical-trials-for-rett-and-pitt-hopkins-syndromes-in-colombia 2025-04-29T16:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/5dd056182646f862/first-patient-enrolled-in-clinical-trial-evaluating-relizorb-for-pancreatitis-patients-with-epi 2025-04-29T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/b066fc9e976ccb85/acousia-therapeutics-reaches-50-enrollment-in-phase-2-trial-for-cisplatin-induced-hearing-loss-prevention 2025-04-29T16:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/17cf6a6b467a953b/roosterbio-and-thermo-fisher-scientific-form-strategic-partnership-to-accelerate-cell-and-exosome-therapy-development 2025-04-29T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/a5dd840ca84a67fb/tepylute-a-ready-to-dilute-formulation-of-thiotepa-now-available 2025-04-29T15:46:43+00:00 hourly 0.9 https://trial.medpath.com/news/33bf0b44368d3d86/novartis-accelerates-23-billion-us-manufacturing-investment-as-ceo-warns-of-devastating-drug-pricing-controls 2025-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/a717e2f2114b7c40/glp-1-receptor-agonists-show-promise-in-secondary-prevention-of-atrial-fibrillation 2025-04-29T14:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/cd056119412c973b/atossa-therapeutics-unveils-smart-2-0-study-to-reduce-interval-breast-cancer-in-high-risk-women 2025-04-29T13:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/f99115af8ab12a3c/novel-btk-inhibitor-combination-shows-promise-in-primary-cns-lymphoma-trial 2025-04-29T13:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/3031e58f2ee981ce/vesicor-therapeutics-to-go-public-via-70m-spac-merger-advancing-novel-p53-cancer-therapy 2025-04-29T13:35:08+00:00 hourly 0.9 https://trial.medpath.com/news/1b3ed8738a926080/american-heart-association-awards-1m-to-study-glp-1-medications-impact-on-cardiovascular-risk 2025-04-29T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/2ab8c2feee83b6d6/fda-misses-deadline-for-stealth-biotherapeutics-rare-barth-syndrome-drug-elamipretide 2025-04-29T13:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/5b69e3c028a8ec03/biomay-receives-fda-approval-for-cas9-nuclease-manufacturing-expanding-crispr-therapy-supply-chain 2025-04-29T13:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/b4aace492bb90466/artiva-s-allonk-shows-promising-durability-in-b-cell-non-hodgkin-lymphoma-matching-car-t-efficacy 2025-04-29T13:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/0698f02ba8cd8d6a/chla-pioneers-pig-heart-xenotransplantation-study-for-critically-ill-infants 2025-04-29T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/72c9347c629f53fd/fda-commissioner-assures-drug-review-timelines-will-be-met-despite-mass-layoffs 2025-04-29T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/7fbecb75519dccdd/henlius-and-sandoz-partner-on-ipilimumab-biosimilar-in-301-million-deal-to-expand-global-access 2025-04-29T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/ad061f209447ba5f/sangamo-therapeutics-to-showcase-breakthrough-prion-disease-treatment-at-asgct-annual-meeting 2025-04-29T10:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/55c95ea301e969d6/shape-therapeutics-to-present-breakthrough-rna-editing-data-for-cns-therapies-at-asgct-annual-meeting 2025-04-29T10:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/ce301220bbddedbd/astrazeneca-halts-phase-3-trial-of-capivasertib-for-metastatic-castration-resistant-prostate-cancer 2025-04-29T10:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/31ea5ec6234bbcd5/dyno-therapeutics-unveils-three-ai-designed-aav-capsids-for-enhanced-gene-therapy-delivery 2025-04-29T10:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/273328a1d25ce0e7/kytopen-forges-strategic-partnerships-to-revolutionize-cell-therapy-manufacturing-with-non-viral-engineering-platform 2025-04-29T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/bd40baddb036c32c/therini-bio-s-thn391-shows-promise-in-phase-1a-trial-for-neurodegenerative-diseases 2025-04-29T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/147e32525cd18b71/fate-therapeutics-to-showcase-innovative-off-the-shelf-car-t-cell-platform-at-asgct-annual-meeting 2025-04-29T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b3e6b477067d7cf/tempus-introduces-xm-liquid-biopsy-assay-to-monitor-immunotherapy-response-in-advanced-solid-tumors 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/7167c1ad13b6fcd0/oncocyte-s-blood-based-transplant-rejection-assay-shows-long-term-clinical-validity-in-13-year-study 2025-04-29T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5b84811b7ab70a78/prometheus-laboratories-unveils-groundbreaking-pre-therapy-test-for-ibd-biologic-response-prediction 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/325694dd061ac9e1/alxn1840-shows-promising-long-term-efficacy-and-safety-for-wilson-disease-at-easl-2025 2025-04-29T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3af22cdc1cd0b0a/bdr-pharmaceuticals-plans-100-million-u-s-expansion-to-boost-global-footprint 2025-04-29T07:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/58ac45e3f453ec08/first-patient-dosed-with-psv359-in-perspective-therapeutics-phase-1-2a-trial-for-fap-a-positive-solid-tumors 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/25eebad451392abe/scaleready-awards-g-rex-grants-to-advance-novel-car-t-cell-therapy-manufacturing 2025-04-29T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/135120c92591ec3d/flatiron-health-to-showcase-ai-powered-real-world-oncology-data-research-at-ispor-2025 2025-04-29T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b6c61acda6ebd586/community-engagement-emerges-as-critical-bridge-between-cancer-research-and-policy-development 2025-04-29T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/5861e261aac85c63/paradigm-shift-in-iga-nephropathy-treatment-novel-targeted-therapies-address-disease-mechanisms 2025-04-29T02:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/8b0c6648bec0b313/personalized-treatment-approaches-for-relapsed-refractory-follicular-lymphoma-navigating-third-line-therapy-options 2025-04-29T02:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/5b5884ecc5424b35/pacira-s-gene-therapy-demonstrates-sustained-efficacy-in-knee-osteoarthritis-trial 2025-04-29T01:56:45+00:00 hourly 0.9 https://trial.medpath.com/news/7bafd91b28e6577d/embark-trial-testosterone-levels-recover-in-most-men-after-prostate-cancer-treatment-suspension 2025-04-29T01:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/fff9ff5f225e8dba/stablepharma-begins-phase-1-trial-of-world-s-first-fridge-free-tetanus-diphtheria-vaccine 2025-04-29T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/e15b71c2e3fb5a18/deepull-raises-eur50-million-in-series-c-to-advance-rapid-sepsis-diagnostic-technology 2025-04-29T00:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/653486303623c825/capsida-biotherapeutics-advances-novel-gene-therapies-for-cns-disorders-ahead-of-asgct-2025 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2cf6f89d51086dc5/novel-car-t-cell-therapy-shows-100-response-rate-in-refractory-cd30-lymphoma-patients 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7196fcb0dfbda2a7/acc-recommends-first-line-obesity-medications-as-prescribing-disparities-persist-for-semaglutide-and-tirzepatide 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9c4b96744b98beb/invikafusp-alfa-demonstrates-promising-activity-in-immune-checkpoint-inhibitor-resistant-solid-tumors 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a37d44f16066d12b/transverse-medical-secures-over-10m-in-series-b2-funding-to-advance-stroke-prevention-technology 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/84fd697b7d844459/fda-grants-fast-track-designation-to-bioinvent-s-bi-1808-for-cutaneous-t-cell-lymphoma 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d119d56a6183cf0c/cantargia-expands-can10-development-to-target-treatment-resistant-atopic-dermatitis 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/26d377a8cf8e1cb9/fyr-partners-with-mayo-clinic-to-develop-blood-based-biomarkers-for-parkinson-s-disease-using-ai-enabled-platform 2025-04-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/98c5f24c5b8996fd/frontier-medicines-presents-breakthrough-data-on-fmc-220-first-in-class-p53-y220c-activator-for-cancer-treatment 2025-04-28T22:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/8e9b3d5c67acecb8/oramed-pharmaceuticals-invests-36-9-million-in-alpha-tau-medical-to-advance-cancer-radiation-therapy 2025-04-28T22:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/06577a31e8c33bfa/world-first-immunotherapy-trial-aims-to-reprogram-immune-system-in-type-1-diabetes 2025-04-28T22:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/5a34ec47413e1187/j-j-s-tar-200-shows-promising-results-in-bcg-unresponsive-bladder-cancer-trial 2025-04-28T22:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/6c0b0b68064cce58/michigan-senate-approves-prescription-drug-affordability-board-to-combat-rising-medication-costs 2025-04-28T21:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/2065fd3e68a8b033/scholar-rock-appoints-david-l-hallal-as-ceo-strengthens-leadership-team-ahead-of-apitegromab-launch-for-sma 2025-04-28T20:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/bfe8443bc995c0a2/histosonics-histotripsy-system-achieves-90-local-tumor-control-at-12-months-in-liver-cancer-trials 2025-04-28T20:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/9216a424d66f57e9/immunotherapy-breakthrough-could-replace-traditional-cancer-treatments-in-select-patients 2025-04-28T20:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/77d8a80942e0bb3f/redhill-biopharma-secures-key-chinese-patent-for-covid-19-treatment-rhb-107 2025-04-28T19:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/f84fd1fd39f31bfd/pharmasyntez-to-launch-three-innovative-drugs-with-blockbuster-potential-in-2025-2026 2025-04-28T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/3cdf0cfbff349878/dr-reddy-s-to-launch-sanofi-s-beyfortus-in-india-for-rsv-prevention-in-infants 2025-04-28T19:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/6d6896524945d809/cg-oncology-s-bladder-cancer-drug-shows-promising-durability-in-phase-3-trial 2025-04-28T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/f78d17dccfa3c6a1/yale-s-experimental-cancer-vaccine-shows-remarkable-success-in-canine-clinical-trials 2025-04-28T19:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/0c2f0604839e70fb/ankyra-therapeutics-reports-promising-phase-1-data-for-anchored-il-12-drug-conjugate-in-solid-tumors 2025-04-28T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/699276bb9a9a5cf7/g8-frailty-assessment-tool-predicts-docetaxel-tolerability-in-metastatic-prostate-cancer 2025-04-28T19:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/99fb0fdfbb8bf552/novel-ai-model-progrxn-bca-significantly-improves-nmibc-progression-risk-prediction 2025-04-28T18:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/74c0a8adae087367/bms-986365-shows-promise-in-phase-3-trial-for-advanced-prostate-cancer-resistant-to-standard-therapies 2025-04-28T16:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/65ddd9e4977275ca/theralase-s-ruvidar-shows-promise-as-dub-inhibitor-in-cancer-treatment-breakthrough 2025-04-28T16:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/8ebda1e803911b3e/neoadjuvant-immunochemotherapy-shows-promising-results-in-locally-advanced-oral-squamous-cell-carcinoma 2025-04-28T16:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/c993480a2c8e5908/tempus-unveils-loop-ai-powered-platform-revolutionizes-oncology-target-discovery 2025-04-28T16:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/a18e9fe1511f0942/fda-clears-delcath-s-hepzato-for-phase-2-trial-in-liver-dominant-metastatic-breast-cancer 2025-04-28T16:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/f29847d0e3aa1273/be-biopharma-to-present-promising-nonclinical-data-for-novel-b-cell-therapy-in-hypophosphatasia-treatment 2025-04-28T16:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/66c749548b1c2da1/metrion-biosciences-unveils-breakthrough-nav1-9-screening-assay-to-accelerate-non-opioid-pain-therapeutics-development 2025-04-28T16:34:49+00:00 hourly 0.9 https://trial.medpath.com/news/f386a0af93182594/celltrion-to-present-new-zymfentra-r-data-for-ibd-management-at-2025-digestive-disease-week 2025-04-28T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/199f5eb7216eef1c/kura-oncology-initiates-phase-1-trial-combining-ziftomenib-with-imatinib-for-advanced-gist-treatment 2025-04-28T16:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/16390ccd777d993f/cellectis-advances-gene-editing-with-non-viral-talen-technology-and-tale-base-editors-at-asgct-2025 2025-04-28T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/0d820ba7574f514b/spero-therapeutics-appoints-esther-rajavelu-as-president-and-chief-executive-officer 2025-04-28T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/09853118a9837e2d/anthem-blue-cross-and-blue-shield-approves-coverage-for-reactiv8-neurostimulation-therapy-for-chronic-low-back-pain 2025-04-28T15:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/33dd1fc068be6432/tg-c-shows-promise-as-first-disease-modifying-therapy-for-knee-osteoarthritis-with-15-year-safety-data 2025-04-28T15:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/cae0144d11d65c77/samsung-biologics-surpasses-2-2-billion-in-2025-contract-orders-expands-global-biomanufacturing-capacity 2025-04-28T14:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/0feff9bc8f2b1de1/merck-kgaa-to-acquire-springworks-therapeutics-in-3-9-billion-deal-for-rare-disease-portfolio 2025-04-28T14:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/37c29722b377248e/medicus-pharma-to-acquire-antev-for-75-million-gaining-novel-gnrh-antagonist-for-prostate-conditions 2025-04-28T14:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/4e4ec18041f9fe45/fda-approved-lenire-device-shows-91-5-success-rate-in-real-world-tinnitus-treatment-study 2025-04-28T14:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/a19a229f87d5be24/biohaven-secures-600-million-non-dilutive-funding-from-oberland-capital-for-rare-disease-drug-development 2025-04-28T14:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/7dd64955bd68d92e/talus-bio-unveils-promising-preclinical-data-on-novel-transcription-factor-inhibitors-at-aacr-2025 2025-04-28T13:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/0759dc62a83e4f82/new-biomarker-for-early-parkinson-s-detection-shows-over-90-accuracy-in-clinical-trials 2025-04-28T13:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/002b8857c3caab27/purespring-s-ps-002-receives-ema-orphan-drug-designation-for-iga-nephropathy-treatment 2025-04-28T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/news/62bb934d612a6acb/immvira-reports-favorable-safety-profile-for-oncolytic-virus-mvr-c5252-in-phase-i-glioma-trial 2025-04-28T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/236942638429e0c0/galmed-pharmaceuticals-advances-novel-sublingual-semaglutide-formulation-to-challenge-injectable-glp-1-market 2025-04-28T13:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/d4c839717b84d60a/pretomanid-price-drops-25-boosting-access-to-life-saving-tb-treatment-across-africa 2025-04-28T13:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/77cda7404bd289fd/thermo-fisher-scientific-commits-2-billion-to-expand-us-manufacturing-and-r-d-capabilities 2025-04-28T13:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/a9b4a85252be2d34/fda-approves-adma-biologics-innovative-yield-enhancement-process-for-immune-globulin-production 2025-04-28T13:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/6d81e59130ee5bcf/pci-pharma-services-to-acquire-ajinomoto-althea-expanding-us-fill-finish-capabilities 2025-04-28T13:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/bf730c065d7a164a/strand-therapeutics-unveils-promising-preclinical-data-for-stx-003-mrna-therapy-targeting-solid-tumors 2025-04-28T13:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/bbf640b7563b6503/guardant-health-launches-first-tissue-test-with-comprehensive-multiomic-analysis-for-cancer-profiling 2025-04-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/abb3b7a846050081/revolution-medicines-reports-promising-results-for-zoldonrasib-in-kras-g12d-mutant-lung-cancer 2025-04-28T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/09be4d88a0a24c78/brain-navi-partners-with-first-securities-for-ipo-aims-to-accelerate-global-medtech-expansion 2025-04-28T10:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/154cc5ad1c1f761e/fda-clears-blackfinbio-s-novel-gene-therapy-trial-for-rare-childhood-neurological-disease-spg47 2025-04-28T10:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/2f900ee6b17e138d/radspherin-r-shows-promising-18-month-results-in-ovarian-cancer-trial-with-90-recurrence-free-rate 2025-04-28T10:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/09e77c88daa91040/prilenia-and-ferrer-form-eur500-million-partnership-to-commercialize-pridopidine-for-huntington-s-disease-in-europe 2025-04-28T08:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/8fcd8d243a02e165/telix-pharmaceuticals-faces-fda-setback-for-brain-cancer-imaging-agent 2025-04-28T07:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/0cf579e942008182/senti-bio-s-logic-gated-car-nk-cell-therapy-shows-promising-results-in-aml-clinical-trial 2025-04-28T07:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/70875d2a32de22b2/monte-rosa-presents-promising-preclinical-data-for-cdk2-molecular-glue-degrader-in-hr-positive-breast-cancer-at-aacr-2025 2025-04-28T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b38ef22a608f5be1/total-telcom-subsidiary-secures-100000-plus-royalties-in-strategic-licensing-deal-for-heater-controllers 2025-04-28T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/78a59d6ccbffbc82/elpis-biopharmaceuticals-advances-multi-mechanism-armored-car-t-platform-for-solid-tumors 2025-04-28T05:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/aced171792cea203/y-mabs-presents-preclinical-pharmacokinetics-data-for-cd38-sada-pretargeted-radioimmunotherapy-at-aacr-2025 2025-04-28T04:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/5798c96605f305ce/pfizer-presents-promising-preclinical-data-on-novel-mesothelin-targeting-adc-at-aacr-2025 2025-04-28T04:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/722d316fe6efdbab/advanced-biological-aging-linked-to-30-higher-dementia-risk-new-study-finds 2025-04-28T03:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/e80f687606ea638e/depression-rates-surge-60-over-past-decade-new-nchs-data-reveals 2025-04-28T03:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/5f2453d2074c0c0f/fda-announces-comprehensive-ban-on-petroleum-based-food-dyes-by-2026 2025-04-28T03:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/3522e0716e1c3121/fda-confirms-proteinuria-as-primary-endpoint-for-dimerix-s-dmx-200-phase-3-fsgs-trial 2025-04-28T01:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/42139cd16f89601a/liberty-gold-ceo-cal-everett-retires-after-eight-years-dr-jon-gilligan-named-new-president-and-ceo 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e3c0204e5f915d6/novel-gene-therapy-targeting-cav-1-protein-shows-promise-in-preserving-memory-function-in-alzheimer-s-disease 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/90b996dd225d81e5/uk-performs-first-easee-brain-implant-surgery-for-drug-resistant-epilepsy-at-newcastle-hospitals 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8514e5f1d6176d24/national-lipid-association-advocates-for-universal-lipoprotein-a-testing-to-enhance-cardiovascular-risk-assessment 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c7ffb0911931c12/fakeeh-care-inks-mou-with-fosun-pharma-to-develop-cell-gene-therapies 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d8c974d0ec334489/medicare-coverage-of-glp-1-obesity-drugs-could-add-47-7-billion-to-federal-spending-over-10-years 2025-04-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/87d59cfc1ff1f63b/y-mabs-initiates-phase-1-trial-of-cd38-sada-radioimmunotherapy-for-relapsed-non-hodgkin-lymphoma 2025-04-27T22:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/6b7e07e6d30db64f/precede-biosciences-unveils-breakthrough-liquid-biopsy-platform-for-tumor-gene-expression-at-aacr-2025 2025-04-27T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/07d8f164876df3c4/zealand-pharma-considers-accelerating-obesity-drug-launch-following-landmark-roche-partnership 2025-04-27T22:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/c20beaa86b96b5ea/novel-off-the-shelf-car-nk-cell-therapy-shows-complete-remission-in-relapsed-aml-patients 2025-04-27T22:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/a6b3cc51a9221ef4/novel-topical-gel-successfully-treats-painful-skin-rash-from-colorectal-cancer-therapy 2025-04-27T22:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/51d606997673f027/abpro-and-celltrion-s-abp-102-ct-p72-shows-promise-as-best-in-class-her2-t-cell-engager 2025-04-27T19:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/584eaa8056e7c352/abbott-s-groundbreaking-aveir-leadless-pacemaker-shows-promise-in-first-in-human-conduction-system-pacing-study 2025-04-27T19:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/261f6aaf984dfe0e/immunotherapy-alone-successfully-treats-multiple-cancer-types-with-mmrd-mutation-eliminating-need-for-surgery 2025-04-27T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/fff057316647e95c/dostarlimab-shows-promise-in-eliminating-need-for-surgery-across-multiple-dmmr-cancer-types 2025-04-27T19:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/5eb640111ced7860/immunotherapy-breakthrough-pembrolizumab-doubles-disease-free-survival-in-locally-advanced-head-and-neck-cancer 2025-04-27T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/d36689478e95bade/springworks-anticipates-chmp-opinion-on-nirogacestat-for-desmoid-tumors-in-q2-2025 2025-04-27T16:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/a36b99f1d74124a9/uniphar-launches-10th-cell-and-gene-therapy-project-expanding-global-access-to-advanced-treatments 2025-04-27T13:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/028c0cde76aeb542/zenflow-s-spring-system-shows-durable-three-year-benefits-for-bph-patients-in-landmark-study 2025-04-27T13:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/103f0dbdd2e86ae7/abbott-s-volt-pfa-system-shows-impressive-12-month-results-for-atrial-fibrillation-treatment 2025-04-27T10:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/c3e8d547c7ad51bd/atezolizumab-shows-improved-survival-in-newly-diagnosed-glioblastoma-patients-with-high-immune-infiltration 2025-04-27T07:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/7a035d968f0cd753/fda-grants-gras-status-to-bestzyme-s-melliatm-brazzein-advancing-zero-calorie-sweetener-market 2025-04-27T04:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/7ef19d66df94aed7/medtronic-s-afferatm-pfa-technologies-show-promising-results-for-atrial-fibrillation-treatment 2025-04-27T02:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/aaa88b5ace6d6ddf/lee-health-heart-institute-reaches-100-patient-milestone-in-global-leapps-stroke-prevention-trial 2025-04-27T01:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/b0268dfe55f0a182/structured-linezolid-dose-reduction-shows-promise-in-drug-resistant-tb-treatment 2025-04-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cc334e4d9b9e7451/india-launches-first-indigenous-hpv-test-kits-for-cervical-cancer-screening 2025-04-26T22:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/4aca335e8abfb0a7/lifitegrast-shows-long-term-safety-and-efficacy-for-dry-eye-disease-in-7-year-analysis 2025-04-26T22:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/600fa57931daf390/fda-approves-trofinetide-as-first-ever-treatment-for-rett-syndrome-opening-new-era-for-rare-genetic-disorder 2025-04-26T22:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/279030ffca8e21ab/ema-recommends-approval-of-tepezza-for-thyroid-eye-disease-first-targeted-treatment-in-eu 2025-04-26T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/0ee0475af0f295c7/medtronic-s-hugo-robotic-surgery-system-meets-primary-endpoints-in-landmark-urologic-trial 2025-04-26T19:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/8b778540c5e29be7/spyglass-pharma-s-iol-mounted-drug-delivery-platform-shows-promising-18-month-results-for-glaucoma-patients 2025-04-26T19:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/f3bd7d25afefa1a6/biocon-biologics-receives-positive-chmp-opinions-for-denosumab-biosimilars-in-europe 2025-04-26T16:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/cc0eeb67147b0746/intensity-therapeutics-secures-2-35-million-in-public-offering-to-advance-cancer-immunotherapy-trials 2025-04-26T08:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/353abc2458061525/city-of-hope-to-present-groundbreaking-cancer-research-at-aacr-annual-meeting-2025 2025-04-26T07:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/70fd3a5156e6c0ec/keymed-biosciences-advances-novel-cdh17-targeted-adc-for-gastrointestinal-cancers-with-ind-approval-in-china 2025-04-26T04:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/423a233bdbe46ed2/nccn-updates-guidelines-to-recommend-dpyd-testing-before-fluoropyrimidine-chemotherapy 2025-04-26T03:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/f2c9f74b063ff552/study-reveals-age-specific-disease-burdens-in-pediatric-and-adolescent-atopic-dermatitis-patients 2025-04-26T03:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/02363d5db9866816/clinical-ink-launches-triallens-ai-powered-analytics-dashboard-transforms-clinical-trial-data-management 2025-04-26T02:33:22+00:00 hourly 0.9 https://trial.medpath.com/news/394e52a71511a975/biohaven-withdraws-eu-application-for-troriluzole-in-spinocerebellar-ataxia-rbc-remains-optimistic 2025-04-26T02:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/a8318a8c7a8e1361/fda-approves-medtronic-s-omniasecure-world-s-smallest-defibrillation-lead-for-cardiac-patients 2025-04-26T01:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/24ed4c08a6de8035/johnson-johnson-medtech-reports-promising-3-month-data-for-omnypulse-platform-in-atrial-fibrillation-treatment 2025-04-26T01:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/b63cdc7276d7a085/proposed-25-pharmaceutical-tariffs-could-increase-us-drug-costs-by-51-billion-annually 2025-04-25T23:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/9b1cce9f3cbf7f9d/fda-requests-additional-trial-for-novavax-covid-19-vaccine-before-full-approval 2025-04-25T22:40:26+00:00 hourly 0.9 https://trial.medpath.com/news/8904055d236a92c5/veracyte-expands-decipher-prostate-test-to-metastatic-cancer-patients-offering-new-treatment-guidance-tool 2025-04-25T22:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/a42d4ece3d9e0d3e/myriad-genetics-precise-mrd-test-shows-promise-for-personalized-treatment-in-renal-cell-carcinoma 2025-04-25T22:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/acb9c8fecbb20f85/md-anderson-researchers-present-breakthrough-cancer-therapies-at-aacr-2025 2025-04-25T22:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/cec4f2e6b1618c6d/aacr-annual-meeting-2025-to-bridge-gap-between-cancer-science-and-clinical-practice 2025-04-25T22:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/4ef3345c36133d8b/billiontoone-to-showcase-advanced-liquid-biopsy-innovations-at-aacr-2025 2025-04-25T20:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/f7eba96940242c16/uk-court-of-appeal-grants-astrazeneca-interim-injunction-against-glenmark-s-generic-dapagliflozin 2025-04-25T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/7db1d21d9342af9b/nimbus-therapeutics-initiates-first-in-human-trial-of-ndi-219216-for-msi-h-tumors-resistant-to-standard-therapies 2025-04-25T19:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/b91e35666af178be/leap-therapeutics-fl-501-shows-promise-in-reversing-cancer-cachexia-in-preclinical-studies 2025-04-25T19:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/de19f374a0dff3f0/amgen-announces-900-million-manufacturing-expansion-in-ohio-creating-350-new-jobs 2025-04-25T19:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/89f36cfcd09502f6/akeso-secures-fda-approval-for-novel-cancer-drug-while-partner-summit-therapeutics-faces-sharp-stock-decline 2025-04-25T19:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/09cdf5d6e73e99be/dana-farber-researchers-present-breakthrough-cancer-studies-at-aacr-2025-annual-meeting 2025-04-25T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/7cea226363536812/smart-drug-delivery-systems-market-poised-for-17-growth-as-chronic-disease-management-evolves 2025-04-25T19:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/e147701228590ea9/biohaven-withdraws-eu-application-for-spinocerebellar-ataxia-drug-dazluma 2025-04-25T19:36:04+00:00 hourly 0.9 https://trial.medpath.com/news/45aec62cf91452c1/emercell-receives-ema-approval-to-study-allogeneic-nk-cell-therapy-for-diffuse-large-b-cell-lymphoma 2025-04-25T19:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/f6ab691122097201/ema-s-role-in-regulatory-reliance-for-post-approval-changes 2025-04-25T19:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/a58dfa75530aa51a/uk-court-of-appeal-grants-astrazeneca-injunction-against-glenmark-s-diabetes-generic 2025-04-25T19:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/78a9218119abc672/suven-pharmaceuticals-and-cohance-lifesciences-merger-approved-creating-1-billion-cdmo-powerhouse 2025-04-25T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/bed7c2d81fd257bf/olema-s-kat6-inhibitor-op-3136-shows-promising-anti-tumor-activity-across-multiple-cancer-types 2025-04-25T19:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/121b499c82928830/pneumonia-antibiotic-piperacillin-shows-promise-as-targeted-lyme-disease-treatment-at-100-fold-lower-doses 2025-04-25T18:23:12+00:00 hourly 0.9 https://trial.medpath.com/news/c39f58a3ea6afbb1/lupin-limited-sets-new-benchmark-with-india-s-largest-diabetes-real-world-evidence-study 2025-04-25T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/cde2f6fdbebb5f5a/alx-oncology-s-cd47-inhibitor-combination-with-keytruda-fails-in-dual-phase-ii-trials 2025-04-25T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/dda6ecf784992954/cdr-life-s-novel-t-cell-engagers-show-superior-potency-against-solid-tumors-in-preclinical-studies 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d2ba3b82fd82f980/catalym-s-visugromab-shows-promise-in-enhancing-antibody-drug-conjugate-efficacy-by-blocking-gdf-15 2025-04-25T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f00d1394c4d1bddc/vivavision-s-vvn461-shows-promising-results-in-phase-2-trial-for-non-infectious-anterior-uveitis 2025-04-25T16:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/c7368cb8518120cf/chmp-recommends-approval-of-oczyesa-for-acromegaly-treatment-in-the-eu 2025-04-25T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/a3262c4d7315b782/ptc-therapeutics-sephience-receives-positive-chmp-opinion-for-phenylketonuria-treatment-across-all-age-groups 2025-04-25T16:35:57+00:00 hourly 0.9 https://trial.medpath.com/news/f46fa7421e426655/global-clinical-trial-launches-to-test-sipavibart-as-potential-long-covid-treatment 2025-04-25T16:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/6e493d58c9726f0c/caribou-biosciences-restructures-abandons-autoimmune-program-to-focus-on-cancer-cell-therapies 2025-04-25T16:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/5fcd96c717cd1148/evorpacept-keytruda-combination-fails-to-meet-primary-endpoints-in-head-and-neck-cancer-trials 2025-04-25T16:35:39+00:00 hourly 0.9 https://trial.medpath.com/news/156c9f1aa44db31f/queen-elizabeth-hospital-leads-uk-recruitment-in-global-astrazeneca-heart-failure-trial 2025-04-25T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/f251596ab9c83f11/clearb-therapeutics-to-present-promising-preclinical-data-on-hepatitis-b-therapeutic-vaccine-at-easl-2025 2025-04-25T16:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/796d68026c04dbe8/caredx-showcases-extensive-clinical-evidence-for-transplant-monitoring-solutions-at-ishlt-2025 2025-04-25T13:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/16b9cbe4f4e03fa2/genfit-reports-strong-2024-financial-results-with-first-commercial-revenues-from-iqirvo-r 2025-04-25T11:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/29a8dd5a71ecc0f8/hansa-biopharma-appoints-renee-aguiar-lucander-as-new-ceo-marking-new-growth-phase 2025-04-25T10:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/44e2ad389d093776/nordic-pharma-launches-authorized-generic-of-maxitrol-for-bacterial-eye-infections 2025-04-25T10:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/8b9cfc532688aede/syncromune-to-present-phase-1-data-on-novel-sync-t-therapy-for-metastatic-prostate-cancer-at-asco-2025 2025-04-25T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e91507b664ba625/fda-clears-circa-scientific-s-pericrosstm-epicardial-access-kit-with-100-success-rate-in-clinical-trial 2025-04-25T04:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/1b0170d055ed0387/allarity-therapeutics-unveils-novel-predictive-tool-for-daratumumab-response-in-multiple-myeloma-patients 2025-04-25T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b817b7c327e2fa7/pipeline-analysis-reveals-20-therapies-in-development-for-open-angle-glaucoma-treatment 2025-04-25T01:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/b64c75c02ab765e3/avidicure-launches-with-50m-to-develop-novel-multifunctional-antibody-platform-for-cancer 2025-04-25T01:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/07deac79d2d6b51f/briacell-therapeutics-completes-13-8-million-public-offering-to-advance-cancer-immunotherapy-pipeline 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b52931646baac250/cn-bio-and-pharmaron-partner-to-advance-organ-on-a-chip-technology-for-drug-development 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/461d0cea6c637428/bpgbio-s-bpm31510-demonstrates-breakthrough-blood-brain-barrier-penetration-for-mitochondrial-disease-treatment 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fdfec20bafa2c73e/avvio-medical-to-present-novel-urological-device-trial-results-at-2025-aua-annual-meeting 2025-04-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fa0fe3bfe482849b/grove-biopharma-secures-30m-funding-expands-to-new-r-d-facility-in-chicago-s-fulton-market 2025-04-24T23:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/82bc6b2a55765805/circle-pharma-to-reveal-dual-mechanism-of-novel-cyclin-a-b-rxl-inhibitors-at-aacr-2025 2025-04-24T23:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/8e977dd120a71150/montana-pioneers-experimental-treatment-hub-with-new-legislation-expanding-right-to-try 2025-04-24T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b78110699b6bcf17/lumicera-and-costco-partner-to-expand-cost-plus-specialty-pharmacy-services-for-chronic-and-rare-conditions 2025-04-24T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/8eabda8aeec969e5/araceli-biosciences-secures-11-2m-seed-funding-to-accelerate-ai-powered-drug-discovery-imaging 2025-04-24T22:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/d1b36693bf972dfd/corwave-s-novel-lvad-shows-promising-results-in-6-month-preclinical-study-advancing-to-human-trials 2025-04-24T22:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/8c8d75822be50ea0/biocon-launches-4500-crore-qip-to-strengthen-balance-sheet-and-reduce-debt 2025-04-24T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/633546fd0abd339f/guardant-health-and-pfizer-form-strategic-alliance-to-advance-cancer-therapies-using-liquid-biopsy-technology 2025-04-24T20:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/61fadabf45cf7701/topas-therapeutics-to-present-promising-phase-2a-data-for-novel-celiac-disease-treatment-at-ddw-2025 2025-04-24T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/f69ecb29e367ebda/mosaic-therapeutics-acquires-two-clinical-stage-oncology-programs-from-astex-to-develop-novel-combination-therapies 2025-04-24T19:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/704f91209175e534/abbvie-seeks-fda-approval-for-novel-serotype-e-botulinum-neurotoxin-for-glabellar-lines 2025-04-24T19:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/aac14a98720edf22/amplifier-health-and-xeomics-partner-to-advance-voice-based-diagnostic-ai-with-750000-global-voice-samples 2025-04-24T19:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/d1a776c357202afa/arrowhead-s-plozasiran-for-familial-chylomicronemia-syndrome-fast-tracked-for-eu-approval 2025-04-24T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/95fc2fe0c47faa74/medtronic-submits-interoperable-insulin-pump-to-fda-advancing-abbott-partnership 2025-04-24T19:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/c07a0718247ce63d/sanofi-halts-balinatunfib-monotherapy-development-after-phase-ii-psoriasis-trial-miss 2025-04-24T19:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/2027e92bd30d97ed/sarcopenia-pipeline-shows-robust-growth-with-18-pharma-companies-developing-novel-therapies 2025-04-24T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/150c835396153d4b/cytoagents-advances-phase-1b-2a-trial-of-cto1681-for-cytokine-release-syndrome-in-car-t-cell-therapy-patients 2025-04-24T17:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/d21ea23b5726cfc9/dt-109-novel-glycine-based-compound-shows-dual-efficacy-against-atherosclerosis-and-mash 2025-04-24T17:33:21+00:00 hourly 0.9 https://trial.medpath.com/news/9eb134144c4e3409/promising-alzheimer-s-vaccine-targeting-tau-protein-advances-toward-human-trials 2025-04-24T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/75a4863c07d9e2b5/fda-sets-q3-2025-approval-dates-for-three-breakthrough-therapies-targeting-rare-diseases 2025-04-24T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/ea2ed96476cdd94b/india-conducts-first-human-gene-therapy-trial-for-hemophilia-in-landmark-collaboration 2025-04-24T16:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/382b4ca6ccd24b28/veraxa-biotech-and-voyager-acquisition-to-merge-creating-1-64b-nasdaq-listed-cancer-therapeutics-company 2025-04-24T16:37:23+00:00 hourly 0.9 https://trial.medpath.com/news/d00b512d170d3173/renibus-completes-enrollment-in-pivotal-phase-3-protect-trial-of-rbt-1-for-cardiac-surgery-complications 2025-04-24T16:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/a89c970d7bb5a682/entod-pharmaceuticals-receives-first-global-approval-for-0-05-atropine-eye-drops-to-combat-childhood-myopia 2025-04-24T16:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/058f08f904b45963/liverpool-researchers-trial-oral-treatment-for-deadly-leishmaniasis-disease 2025-04-24T16:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/401c97754bb35a5c/cocrystal-pharma-s-antiviral-cdi-988-shows-potent-activity-against-emerging-norovirus-variants 2025-04-24T16:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/acae1ba01d798526/ireland-launches-magic-i-first-national-genomics-study-to-transform-childhood-cancer-care 2025-04-24T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/6907eb550e758f71/vir-biotechnology-to-present-key-hepatitis-b-and-delta-clinical-data-at-easl-congress-2025 2025-04-24T16:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/7ec3f000adc4ada8/seed-therapeutics-advances-dual-breakthrough-programs-in-targeted-protein-degradation-at-aacr-2025 2025-04-24T16:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/4017efc9b334267d/akoya-biosciences-launches-advanced-adc-breast-cancer-assay-for-precision-oncology 2025-04-24T16:35:03+00:00 hourly 0.9 https://trial.medpath.com/news/922deae091278e58/granite-bio-emerges-with-100m-funding-and-novel-immunology-pipeline-for-ibd-and-allergies 2025-04-24T16:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/3d6e950619ddde91/fda-approves-ferring-pharmaceuticals-new-manufacturing-facility-for-bladder-cancer-gene-therapy-adstiladrin 2025-04-24T16:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/875126ded524b886/inhalerx-secures-38-5-million-funding-to-advance-novel-inhaled-therapies-for-cancer-pain-and-panic-disorder 2025-04-24T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/284e3fb33651a324/novel-non-hormonal-male-contraceptive-adam-shows-two-year-efficacy-in-clinical-trials 2025-04-24T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/2932bbd27b25a1e3/koelis-and-bot-image-partner-to-enhance-prostate-cancer-detection-with-ai-powered-fusion-biopsy-technology 2025-04-24T16:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/e14de38cef273cac/cell-therapy-advances-show-promise-for-hepatocellular-carcinoma-treatment 2025-04-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7c8fd4cd2bfc5d6/varenicline-shows-promising-results-for-youth-vaping-cessation-in-landmark-trial 2025-04-24T14:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/122508f35474544b/boston-scientific-s-farapulse-pfa-system-shows-promising-results-for-persistent-atrial-fibrillation-treatment 2025-04-24T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/62d1d84a89191553/single-dose-baloxavir-significantly-reduces-household-influenza-transmission-in-global-phase-iii-trial 2025-04-24T13:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/3b925ce1c1e68a4a/promising-pipeline-for-mantle-cell-lymphoma-treatment-22-therapies-under-development-by-20-companies 2025-04-24T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/031520ab4ea4d1f4/etiome-emerges-with-50m-to-target-disease-biomarkers-before-symptoms-appear 2025-04-24T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/a0fa3c7b4d7d1517/summit-s-ivonescimab-shows-promise-in-phase-iii-trial-against-established-lung-cancer-therapies 2025-04-24T13:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/069e5c40369b302f/medit-and-graphy-form-strategic-alliance-to-transform-digital-orthodontics-with-3d-printed-clear-aligners 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/03a65c1905939896/geovax-s-multi-antigen-covid-19-vaccine-shows-promising-results-in-immunocompromised-patients 2025-04-24T11:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/4c11be1459bcfe1a/hydrogel-coated-membranes-reduce-t-cell-exhaustion-in-car-t-manufacturing 2025-04-24T11:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/5a58e9baede40aee/ipsen-s-elafibranor-shows-promise-in-phase-ii-trial-for-primary-sclerosing-cholangitis 2025-04-24T10:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/42427fe7ddf9f060/cytovation-secures-6m-funding-to-advance-cy-101-cancer-therapy-into-phase-ii-trials 2025-04-24T10:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/0affb5a1083070db/sun-pharma-and-moebius-medical-s-mm-ii-shows-promising-results-for-knee-osteoarthritis-in-phase-2b-trial 2025-04-24T10:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/a02a752aee70a159/lotte-biologics-launches-dedicated-adc-manufacturing-facility-with-first-client-contract 2025-04-24T10:36:21+00:00 hourly 0.9 https://trial.medpath.com/news/1cdec45c584a5f3d/debiopharm-and-oncodesign-services-partner-to-advance-radiopharmaceutical-research-with-abylinktm-technology 2025-04-24T10:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/b3511201cba3e79a/turbine-unveils-first-ever-virtual-lab-platform-for-cell-simulations-in-drug-development 2025-04-24T10:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/e40b9473444fc01c/archetype-therapeutics-to-present-ai-discovered-lung-cancer-drug-candidates-at-aacr-2025 2025-04-24T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/72e70849a4b2940a/antengene-to-showcase-six-innovative-cancer-therapies-at-aacr-and-asco-2025 2025-04-24T07:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/595a85f3cc72a825/selution-slr-drug-eluting-balloon-shows-exceptional-3-year-patency-rates-in-peripheral-artery-disease-trials 2025-04-24T06:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9e55c74d542d5d9/sagemedic-s-3d-microtumor-assay-shows-promise-for-personalized-cancer-treatment-at-aacr-2025 2025-04-24T05:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/c1ee1d9671e09ff0/ono-pharma-to-present-positive-phase-2-data-for-tirabrutinib-in-pcnsl-and-ono-4578-in-rectal-cancer-at-asco-2025 2025-04-24T04:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/c155509cf64eb342/jak-inhibitor-selection-in-myelofibrosis-balancing-anemia-management-with-disease-control 2025-04-24T03:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/ecbcf04472632ff0/vanda-pharmaceuticals-battles-fda-over-gastroparesis-drug-hearing-delays 2025-04-24T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/c322edc3b554104e/orphan-therapeutics-accelerator-pioneers-novel-funding-model-to-rescue-ultra-rare-disease-treatments 2025-04-24T02:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/063203853cde4e95/innovent-biologics-to-present-breakthrough-clinical-data-for-ibi363-pd-1-il-2-bispecific-antibody-at-asco-2025 2025-04-24T01:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/a89ee153b5b28058/grail-to-present-real-world-data-from-100000-galleri-multi-cancer-detection-tests-at-aacr-2025 2025-04-24T01:36:44+00:00 hourly 0.9 https://trial.medpath.com/news/30e2bc6e4a8524ed/itm-and-alpha-9-oncology-partner-to-supply-rare-actinium-225-for-advanced-cancer-therapies 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f2bf0dd39563c1ed/leo-pharma-s-delgocitinib-cream-outperforms-alitretinoin-in-landmark-delta-force-trial-for-chronic-hand-eczema 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/90748fe735d0ea44/real-world-safety-analysis-reveals-increased-kidney-and-liver-toxicity-with-pembrolizumab-chemotherapy-combination-in-lung-cancer 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1bab49626b12b3a6/oncolytics-biotech-to-present-pelareorep-data-for-pancreatic-cancer-at-asco-2025 2025-04-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8105bbe0ede404b6/rezolute-secures-90-million-in-public-offering-to-advance-rare-disease-therapies 2025-04-23T23:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/463adad41009ef19/long-term-follow-up-of-transform-trial-shows-sustained-benefits-of-liso-cel-car-t-cell-therapy-in-relapsed-lbcl 2025-04-23T22:37:30+00:00 hourly 0.9 https://trial.medpath.com/news/042213144b47ebcd/sickle-cell-disease-pipeline-shows-robust-growth-with-60-therapies-in-development-across-multiple-clinical-phases 2025-04-23T22:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/8253e1dd54109673/sakar-healthcare-secures-second-eu-marketing-authorization-for-colorectal-cancer-treatment 2025-04-23T22:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/47b9cb96225373d2/pfizer-to-showcase-breakthrough-cancer-therapies-at-asco-2025-with-over-60-presentations 2025-04-23T22:36:09+00:00 hourly 0.9 https://trial.medpath.com/news/a904e0fe5343f49d/fda-warns-of-serious-side-effects-from-unapproved-topical-finasteride-hair-loss-treatments 2025-04-23T22:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/7d48bac79bd897ee/astrazeneca-and-tempus-ai-forge-200-million-oncology-ai-partnership-to-accelerate-cancer-drug-discovery 2025-04-23T20:36:57+00:00 hourly 0.9 https://trial.medpath.com/news/4ea6fa4256772ae8/vertex-s-cystic-fibrosis-drug-alyftrek-receives-chmp-recommendation-for-eu-approval 2025-04-23T19:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/2200f17c18991d6a/ema-grants-orphan-drug-designation-to-ab8939-for-acute-myeloid-leukemia-treatment 2025-04-23T19:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/51fc903fa66bba0a/fda-approves-fermentalg-and-givaudan-s-acid-stable-natural-blue-food-colorant 2025-04-23T19:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/db465c4c808ff1dc/chimeric-therapeutics-raises-6-6-million-to-advance-novel-car-t-and-nk-cell-cancer-therapies 2025-04-23T19:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/ca042863564d6ccd/nanostics-begins-clinical-utility-study-for-ai-powered-prostate-cancer-test 2025-04-23T19:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/b41534971f4f2333/biopoly-begins-fda-approved-clinical-trial-for-novel-knee-cartilage-implant 2025-04-23T19:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/de65096075a104f0/new-research-reveals-how-vagus-nerve-encodes-immune-signals-during-inflammation 2025-04-23T19:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/d65f9854f3f525e4/fda-approved-apremilast-shows-dual-potential-for-alcohol-use-disorder-and-pain-management 2025-04-23T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/d28b77240cb2d45d/akeso-reports-positive-phase-3-results-for-ivonescimab-in-lung-cancer-building-on-recent-fda-approval-success 2025-04-23T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/531bf96ac6db1c9d/tempus-ai-astrazeneca-and-pathos-ai-form-200m-collaboration-to-build-oncology-foundation-model 2025-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/5785341339a0ee9e/sk-bioscience-secures-landmark-victory-against-moderna-in-korean-mrna-patent-dispute 2025-04-23T16:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/4b3bf5607d8106c8/baebies-secures-fda-breakthrough-designation-for-first-point-of-care-heparin-monitoring-test 2025-04-23T16:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/09f0a70a3ddc5ab3/trustpoint-and-hexagon-secure-1-2m-navair-contract-to-develop-revolutionary-c-band-gnss-technology 2025-04-23T16:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/b867fe38a5b20b6d/breakthrough-t1d-invests-2-8-million-to-establish-joint-cardiorenal-center-of-excellence-for-type-1-diabetes-research 2025-04-23T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/1b4652f5692dc9e7/oncohost-s-plasma-proteomics-research-reveals-key-mechanisms-of-immunotherapy-resistance-in-nsclc 2025-04-23T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/00c3784490efdb64/ensysce-biosciences-secures-patent-for-novel-methadone-based-opioid-use-disorder-treatment 2025-04-23T16:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/2ed1eb56957a5dda/cerevasc-s-eshunt-system-receives-fda-breakthrough-designation-for-pediatric-hydrocephalus-treatment 2025-04-23T16:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/45a684c11ae400c3/tegoprazan-outperforms-standard-ppi-therapy-in-phase-3-gerd-trials 2025-04-23T16:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/4e6f48c77abebfc7/boehringer-ingelheim-and-tessellate-bio-form-eur500m-partnership-to-target-alt-positive-cancers 2025-04-23T16:36:32+00:00 hourly 0.9 https://trial.medpath.com/news/4bdb8a657f6abe00/novocure-s-phase-3-panova-3-trial-shows-promising-results-for-pancreatic-cancer-treatment 2025-04-23T16:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/4a1aec25b17cd9ec/peanut-allergy-treatment-market-poised-for-16-growth-as-new-therapies-enter-pipeline 2025-04-23T16:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/a95adf7def455076/fda-grants-breakthrough-status-to-mursla-bio-s-evoliver-test-for-early-liver-cancer-detection 2025-04-23T16:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/cb0f44b353ebf387/qiagen-unveils-advanced-cancer-genomic-profiling-tools-at-aacr-2025 2025-04-23T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/90e7b2bbd73a5f89/lakeshore-biopharma-launches-first-needle-free-rabies-vaccine-reconstitution-system-in-china 2025-04-23T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/7670d5e924f06e8c/genentech-partners-with-repertoire-immune-medicines-in-765m-deal-for-autoimmune-disease-drug-discovery 2025-04-23T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/b2dd0c8b0d6f32d3/zealand-pharma-appoints-utpal-singh-as-cso-to-advance-peptide-therapeutics-for-obesity 2025-04-23T16:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/d6a381b4de2e350a/cardiff-oncology-secures-second-patent-for-onvansertib-in-bevacizumab-naive-mcrc-patients 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/16a9b6bc8b70d7b8/sylvester-comprehensive-cancer-center-to-present-groundbreaking-research-at-asco-2025-annual-meeting 2025-04-23T16:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/69a2966e28662ca6/merus-to-present-petosemtamab-combination-therapy-data-for-head-and-neck-cancer-at-2025-asco-meeting 2025-04-23T15:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/af827bcb9a1f8c43/hawaii-advances-psychedelic-assisted-therapy-research-bill-with-4-million-funding-potential 2025-04-23T15:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/514c83cbb482dde7/semaglutide-shows-promise-for-slowing-biological-aging-and-improving-cognition-in-hiv-patients 2025-04-23T14:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/7379e551587e88a6/cuban-drug-jusvinza-advances-through-phase-iii-trial-for-rheumatoid-arthritis-treatment 2025-04-23T11:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/d1d13fca12222af5/remap-cap-trial-shows-hydrocortisone-reduces-mortality-in-severe-community-acquired-pneumonia 2025-04-23T11:00:14+00:00 hourly 0.9 https://trial.medpath.com/news/b99f0817f006b6f5/galapagos-reverses-course-on-company-split-appoints-henry-gosebruch-as-new-ceo 2025-04-23T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/a94a3c0e909ef5e3/parabilis-medicines-demonstrates-first-ever-degradation-of-erg-in-prostate-cancer-models 2025-04-23T09:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/275bbbb699606912/metavia-s-da-1241-shows-enhanced-hepatoprotective-effects-in-mash-combination-therapy 2025-04-23T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/70422f1506e51422/calidi-biotherapeutics-appoints-eric-poma-as-new-ceo-to-advance-novel-cancer-virotherapy-platform 2025-04-23T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/41a1b2514ba48e6a/zai-lab-to-present-phase-1-data-on-novel-dll3-targeted-adc-for-small-cell-lung-cancer-at-asco-2025 2025-04-23T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/3c4abb8f4bce7936/obi-pharma-s-novel-trop2-adc-obi-902-receives-fda-ind-clearance-for-phase-1-2-trial-using-proprietary-glycobi-r-technology 2025-04-23T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/746d1cb8c201a5d6/fda-clears-avava-s-focal-point-technology-for-acne-scar-treatment-across-all-skin-types 2025-04-23T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/1d46c34ced3108cc/novita-s-fascin-inhibitor-np-g2-044-shows-promising-results-in-phase-2-trial-for-advanced-solid-tumors 2025-04-23T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8776c581ffbd0d4a/mallinckrodt-to-present-five-clinical-studies-on-terlivaz-for-hepatorenal-syndrome-at-ddw-2025 2025-04-23T06:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/4aea7c6c2424e7c3/abtherx-partners-with-rondo-and-spice-biotechnologies-to-accelerate-bispecific-antibody-development-for-cancer-immunotherapy 2025-04-23T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c02e85a5bd9a1b22/pacbio-partners-with-davos-alzheimer-s-collaborative-on-groundbreaking-north-african-dementia-registry 2025-04-23T05:18:27+00:00 hourly 0.9 https://trial.medpath.com/news/39d5a51203846eab/genscript-biotech-and-nsg-bio-form-strategic-partnership-to-accelerate-biotech-innovation-in-singapore 2025-04-23T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/f0c36c9e5f0273ec/ctdna-monitoring-shows-promise-for-predicting-melanoma-recurrence-after-surgery 2025-04-23T02:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/7e58d296f11ab626/arbutus-biopharma-to-present-promising-imdusiran-and-ab-101-data-for-chronic-hepatitis-b-at-easl-congress-2025 2025-04-23T02:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/510c3979c929fd65/bayer-partners-with-concertai-to-accelerate-precision-oncology-drug-development-using-ai 2025-04-23T02:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/661ef4d5ef57d2e0/recursion-s-rec-4881-shows-30-polyp-reduction-in-fap-patients-in-phase-1b-2-trial 2025-04-23T01:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/362d0214061c8487/sonoma-pharmaceuticals-hypochlorous-acid-based-acne-products-gain-uk-regulatory-approval 2025-04-23T01:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/c181959c2c1342f0/sobi-showcases-efanesoctocog-alfa-data-from-xtend-phase-3-program-at-wfh-2025-summit 2025-04-23T01:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/556bf0f5abb83e48/valneva-pfizer-lyme-disease-vaccine-shows-promise-with-strong-booster-response-in-phase-2-trial 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa365ef463253246/lilly-s-olumiant-shows-promise-in-preserving-beta-cell-function-in-type-1-diabetes 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ae2c0e346a04a12f/migraine-treatment-pipeline-shows-robust-activity-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7735f5ae15cf392f/1cell-ai-launches-oncoincytes-revolutionary-multi-modal-cancer-diagnostic-panel-for-precision-oncology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/64f139a7724a1b19/wearable-devices-receives-u-s-patent-for-hybrid-voice-and-gesture-control-technology 2025-04-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb68ea0840044fbb/gene-solutions-and-element-biosciences-form-strategic-alliance-to-expand-ngs-technology-access-across-global-markets 2025-04-22T23:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/07f214acfb32c2e6/galapagos-ceo-paul-stoffels-to-step-down-as-company-splits-into-two-entities 2025-04-22T23:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/3b3df5bb2d5884a8/bristol-myers-squibb-s-cobenfy-fails-to-meet-primary-endpoint-as-adjunctive-schizophrenia-treatment-in-phase-3-arise-trial 2025-04-22T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/061acc2e5aefa3a7/novonesis-invests-5-million-to-expand-biotechnology-operations-in-salem-virginia 2025-04-22T22:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/dde91642fc1ee500/springworks-ogsiveo-expected-to-receive-positive-chmp-opinion-boosting-european-market-potential 2025-04-22T19:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/f94d6731c3c1fdc1/fda-clears-ark-surgical-s-lapbox-power-first-dual-wall-system-for-both-manual-and-power-morcellation 2025-04-22T19:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/4b91da953f782459/metro-international-biotech-initiates-phase-1a-trial-of-novel-nad-booster-mib-725-for-age-related-diseases 2025-04-22T19:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/1146b52bd305017f/elite-clinical-network-and-healthyu-clinics-form-strategic-partnership-to-transform-clinical-research-access 2025-04-22T19:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/63a77e3636a09ad1/axoft-s-ultrasoft-brain-computer-interface-shows-promising-results-in-first-human-trial 2025-04-22T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/efab189f931654e1/halda-therapeutics-appoints-dr-eyal-attar-as-chief-medical-officer-to-advance-novel-riptac-cancer-platform 2025-04-22T17:35:36+00:00 hourly 0.9 https://trial.medpath.com/news/27ebca52b861cf66/smsbiotech-partners-with-u-s-army-to-develop-stem-cell-therapy-for-chemical-warfare-injuries 2025-04-22T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/45e917708cb65d74/fda-expands-luminopia-s-digital-therapeutic-approval-for-amblyopia-treatment-to-children-aged-8-12 2025-04-22T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/d4126d2867684209/biostate-ai-and-weill-cornell-medicine-partner-to-develop-ai-driven-personalized-treatment-models-for-leukemia 2025-04-22T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/2a46be27cbd91f01/immune-checkpoint-inhibitors-equally-effective-in-older-and-younger-cancer-patients-despite-immune-phenotype-differences 2025-04-22T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/1a46eccc77724acd/fda-clears-first-in-class-antibody-drug-conjugate-tgw101-for-advanced-solid-tumor-clinical-trial 2025-04-22T16:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/d646767033af773b/sirona-biochem-forms-strategic-partnership-with-promura-gmbh-secures-3m-investment-for-anti-aging-product-development 2025-04-22T16:39:02+00:00 hourly 0.9 https://trial.medpath.com/news/0b8b0c91e969d59c/eu-biosimilar-filings-opinions-and-approvals 2025-04-22T16:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/c559d9bdbb168dc2/ocumetics-advances-revolutionary-accommodating-intraocular-lens-to-first-in-human-surgery-this-summer 2025-04-22T16:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/e7389fc2d8d5c011/trump-administration-considers-international-reference-pricing-to-slash-u-s-drug-costs 2025-04-22T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/4d20b10ffb00f2f5/perfuze-completes-enrollment-in-pivotal-stroke-treatment-trial-strengthens-leadership-team 2025-04-22T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/2723ebbb1a98263a/roche-and-regeneron-announce-multi-billion-dollar-investments-in-us-manufacturing-amid-tariff-concerns 2025-04-22T16:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/5f6dd2fe44f8cc32/ibio-licenses-first-in-class-antibody-targeting-activin-e-for-obesity-and-cardiometabolic-diseases 2025-04-22T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/6d4611e8b2f95b30/fda-grants-breakthrough-therapy-designation-to-brainchild-bio-s-car-t-cell-therapy-for-fatal-pediatric-brain-tumors 2025-04-22T16:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/f168fe50a7fb642b/fda-grants-breakthrough-device-designation-to-orchestra-biomed-s-avim-therapy-for-hypertension 2025-04-22T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/aca324ed0bc27db3/regeneron-expands-biologic-manufacturing-capacity-with-3-billion-fujifilm-partnership 2025-04-22T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/84d29b0d69b57113/malaysia-strengthens-clinical-research-infrastructure-through-strategic-partnerships-and-record-breaking-trial-activity 2025-04-22T16:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/6d731715b7154c2f/carthera-enrolls-100-patients-in-landmark-sonobird-trial-using-ultrasound-to-breach-blood-brain-barrier-in-glioblastoma 2025-04-22T16:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/3ab8dd9f87a6a0af/neurovation-labs-secures-patent-for-novel-ptsd-biomarker-detection-technology 2025-04-22T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/0c8e647a548dccfa/engineered-microglia-a-revolutionary-approach-to-treating-alzheimer-s-disease 2025-04-22T13:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/e7569918454a4425/design-therapeutics-to-present-phase-1-data-for-novel-fecd-eye-drop-treatment-at-ophthalmology-conference 2025-04-22T11:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/6da69cf31e8d992b/cellenkos-novel-off-the-shelf-treg-cell-therapy-demonstrates-promising-results-in-als-clinical-study 2025-04-22T10:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c975d3d077c0e6c/lipum-s-sol-116-shows-promising-phase-i-results-for-rheumatoid-arthritis-treatment 2025-04-22T10:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/7d000933303c3ccb/invivoscribe-s-labpmm-secures-new-york-state-approval-for-ultra-sensitive-flt3-itd-mrd-assay-in-aml 2025-04-22T10:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/9401596ef2125bdd/1stbio-and-ligachembio-form-strategic-alliance-to-develop-next-generation-oncology-therapeutics 2025-04-22T10:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/f07072c1fa65c513/enhertu-demonstrates-progression-free-survival-benefits-in-advanced-breast-cancer-trial 2025-04-22T10:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/bbfd1acd4902ee2c/vivasure-medical-secures-ce-mark-for-first-fully-absorbable-large-bore-vascular-closure-system 2025-04-22T09:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6dd74dd49b34ca9/guardant-health-s-shield-multi-cancer-detection-test-shows-strong-performance-across-10-cancer-types 2025-04-22T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d5284fc7eff3ded/fda-clears-ensem-therapeutics-ind-for-novel-pi3ka-inhibitor-etx-636-for-advanced-cancer-treatment 2025-04-22T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/6931416a874f01ba/arvinas-to-present-promising-preclinical-data-on-protac-bcl6-degrader-arv-393-at-aacr-2025 2025-04-22T07:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/9f337abe93cacbcd/gut-microbiome-metabolite-hya-shows-promise-for-blood-sugar-management-in-type-1-diabetes 2025-04-22T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/bfe2486c946503fe/personalis-to-present-new-data-on-next-personal-ctdna-test-for-early-cancer-detection-at-major-oncology-conferences 2025-04-22T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d0e513395e7c01cc/novocure-s-optune-lua-receives-ce-mark-for-metastatic-non-small-cell-lung-cancer-treatment 2025-04-22T04:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/b2b0e1167fee8ea2/ernexa-therapeutics-to-present-promising-erna-101-data-for-ovarian-cancer-at-aacr-2025 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec3b14a7d42b3e7b/surveil-dcb-shows-comparable-efficacy-to-in-pact-admiral-with-75-lower-paclitaxel-dose-in-transcend-trial 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3931a8010a309634/transneural-therapeutics-unveils-novel-non-hallucinogenic-neuroplastogens-for-neuropsychiatric-disorders 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9582b4badb63d5a1/minoryx-and-neuraxpharm-submit-new-marketing-authorization-application-for-leriglitazone-in-cerebral-adrenoleukodystrophy 2025-04-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8ef86f78192287dc/breakthrough-at-ut-health-san-antonio-chemical-endocytic-strategy-could-transform-iv-drugs-into-oral-treatments 2025-04-21T23:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/a9fa67f6b5c640d5/fda-grants-orphan-drug-designation-to-neuronos-for-phelan-mcdermid-syndrome-treatment 2025-04-21T22:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/feddd51bddc1edcc/dual-targeted-car-t-cell-therapy-shows-100-response-rate-in-relapsed-refractory-mantle-cell-lymphoma 2025-04-21T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/b628d67dc31f9ffe/experimental-cancer-drug-navitoclax-shows-promise-in-enhancing-tuberculosis-treatment 2025-04-21T19:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/9bda21df8f07267a/vcu-massey-becomes-first-virginia-center-to-offer-robotic-hifu-for-prostate-cancer-treatment 2025-04-21T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/47dda962bc049588/field-medical-secures-40-million-series-a-financing-to-advance-pulsed-field-ablation-for-ventricular-tachycardia 2025-04-21T16:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/70bd499bb8b9cc4b/long-term-study-confirms-hydroxyurea-s-safety-and-efficacy-in-pediatric-sickle-cell-disease 2025-04-21T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/0a778add09187e6a/titan-x-ai-platform-accelerates-development-of-novel-immunoregulatory-therapeutics-for-autoimmune-diseases 2025-04-21T16:40:19+00:00 hourly 0.9 https://trial.medpath.com/news/3effb4d7a1f56ad7/nadofaragene-firadenovec-shows-75-complete-response-rate-in-japanese-phase-3-trial-for-bcg-unresponsive-bladder-cancer 2025-04-21T16:40:14+00:00 hourly 0.9 https://trial.medpath.com/news/697023578995aa09/study-reveals-24-of-difficult-to-control-type-2-diabetes-patients-have-hypercortisolism 2025-04-21T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/news/a7e11e4ee1d02bd2/fda-commissioner-makary-proposes-new-approval-pathway-for-rare-disease-drugs 2025-04-21T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/982a9648d1ffcd35/sunshine-biopharma-launches-generic-everolimus-in-canada-s-2-5b-oncology-market 2025-04-21T16:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/bfdad8bfb9c3c363/mural-oncology-cuts-90-of-workforce-following-failed-cancer-immunotherapy-trials 2025-04-21T16:38:55+00:00 hourly 0.9 https://trial.medpath.com/news/3990c5f8d472537b/vaccinex-s-pepinemab-shows-promise-in-turning-cold-tumors-hot-through-enhanced-immune-response 2025-04-21T16:38:53+00:00 hourly 0.9 https://trial.medpath.com/news/8d76e44c139d870b/stanford-researchers-develop-novel-rna-blood-test-for-cancer-detection-and-treatment-resistance-monitoring 2025-04-21T16:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/80d3d6d048a19c80/genesight-test-reduces-psychiatric-hospitalizations-in-major-depression-patients-study-shows 2025-04-21T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/24bccee16071dca1/icl-to-acquire-lavie-bio-strategic-move-to-advance-ai-driven-agricultural-biologicals 2025-04-21T14:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/329141ca59d8aa16/grand-pharmaceutical-s-stc3141-shows-promise-in-phase-ii-sepsis-treatment-trial 2025-04-21T13:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/f57886194f77cfa8/invivyd-secures-30m-non-dilutive-loan-facility-to-advance-covid-19-antibody-pipeline 2025-04-21T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/05fb87ff8c7f9ba3/fda-grants-orphan-drug-designation-to-ns-229-for-rare-vasculitis-condition 2025-04-21T13:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/7dbc09720c7ebebb/abbvie-enters-indian-oncology-market-with-venetoclax-for-blood-cancer-treatment 2025-04-21T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/bdc170603074cd59/fda-approves-groundbreaking-gene-therapy-for-dystrophic-epidermolysis-bullosa 2025-04-21T13:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/7f3c94446a2335ed/nanog-inhibition-shows-promising-results-in-glioblastoma-treatment-significantly-enhancing-temozolomide-efficacy 2025-04-21T11:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/a4b57e3e60ac7525/fda-approves-dupilumab-for-chronic-spontaneous-urticaria-expanding-treatment-options 2025-04-21T11:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/cb17786b7c848450/vgenomics-and-meril-genomics-form-strategic-alliance-to-transform-precision-medicine-landscape-in-india 2025-04-21T10:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/ad4ff204bc5337ed/cgbio-s-novosis-putty-receives-fda-approval-for-pivotal-us-clinical-trials 2025-04-21T10:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/8ab55348994c8c26/toolgen-files-patent-infringement-lawsuit-against-vertex-over-crispr-gene-therapy-casgevy 2025-04-21T10:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/92dafed25c3fb175/inocras-and-d3b-launch-collaborative-research-to-decode-rare-sinonasal-cancer-genetics 2025-04-21T07:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/e78b5add66db45c5/spring-allergy-management-expert-guidelines-for-comprehensive-patient-care 2025-04-21T04:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/42fa10fe8516a78f/apollo-hospital-and-kims-sunshine-partner-with-medtronic-to-launch-renal-denervation-therapy-centers-for-resistant-hypertension 2025-04-21T01:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/873555fa3db61a4a/taipei-medical-university-and-msd-taiwan-forge-landmark-healthcare-innovation-partnership 2025-04-21T01:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/4367c22981d8cafa/cemiplimab-shows-significant-survival-benefit-in-nsclc-patients-with-brain-metastases-and-high-pd-l1-expression 2025-04-20T22:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/6b87457d5f8c030b/cipla-advances-inhaled-antifungal-therapy-with-phase-iii-trial-approval-for-itraconazole-dry-powder 2025-04-20T19:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/b98c5ad1a3947f14/senate-judiciary-committee-advances-six-bipartisan-bills-to-combat-high-drug-prices 2025-04-20T16:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/d0722c4440ce923c/phase-3-trial-shows-high-dose-radiotherapy-significantly-improves-survival-in-limited-stage-small-cell-lung-cancer 2025-04-20T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/069e9c4be2901e6a/unauthorized-drug-trials-exposed-at-ahmedabad-s-vs-hospital-over-500-patients-affected 2025-04-20T04:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/1a00deba482ff291/f2g-s-novel-antifungal-olorofim-shows-promise-despite-fda-setback-phase-2b-results-published-in-the-lancet 2025-04-19T20:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/cb78864026656298/novel-mini-protein-aky-1189-shows-promise-in-targeted-radiation-delivery-for-multiple-cancer-types 2025-04-19T19:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/402a2691d25cf2b2/u-s-measles-outbreak-reaches-800-cases-marking-largest-since-disease-elimination-in-2000 2025-04-19T19:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/03352b43ecff5e3e/uncomplicated-utis-impose-significant-economic-burden-on-healthcare-systems 2025-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/558615b8839c307f/chime-biologics-and-polpharma-biologics-form-strategic-partnership-to-accelerate-global-biosimilar-development 2025-04-19T16:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/b954264b786ed6a2/biologic-drug-costs-for-psoriasis-more-than-doubled-between-2007-2021-study-reveals 2025-04-19T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/7a9debc523eaebd9/fda-restricts-industry-representatives-on-advisory-committees-to-restore-public-trust 2025-04-19T16:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/139b26fd06cb6ba2/fda-updates-camzyos-label-reduced-monitoring-requirements-and-expanded-patient-eligibility-for-hcm-treatment 2025-04-19T01:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/a65e046529d63bba/former-operation-warp-speed-leader-dr-matthew-hepburn-joins-panther-life-sciences-to-advance-microarray-patch-technology 2025-04-19T01:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/df18bbce25d1d29e/nusano-secures-major-supply-agreements-with-ratio-therapeutics-and-clarity-pharmaceuticals-to-address-critical-radioisotope-shortage 2025-04-19T01:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/9cd8dd88e18d2fdf/fda-approves-medtronic-s-simplera-sync-sensor-for-minimed-780g-system-expanding-cgm-options-for-diabetes-management 2025-04-19T01:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/836ec4fc12a5d13a/compass-pathways-psilocybin-therapy-meets-primary-endpoint-in-largest-depression-trial 2025-04-19T01:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/e8eb0df7312118dd/kyowa-hakko-kirin-partners-with-inveniai-to-accelerate-drug-repurposing-using-ai-technology 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3555aa3f2303ca52/bms-s-opdualag-shows-strong-early-performance-as-first-lag-3-checkpoint-inhibitor-for-melanoma 2025-04-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c73a6bb977c087dd/nference-and-beigene-partner-on-ai-driven-research-to-advance-b-cell-cancer-treatment 2025-04-18T23:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/72c92af87b288ee9/sparx-to-present-phase-1-data-on-novel-dual-checkpoint-inhibitor-spx-303-at-aacr-2025 2025-04-18T20:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/e3f4735fa0ce88a0/wuxi-biologics-achieves-milestone-with-first-commercial-ppq-campaign-at-15000l-single-use-bioreactor-facility 2025-04-18T20:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/801ddb542d78bf87/31-gene-expression-profile-test-safely-identifies-melanoma-patients-who-can-avoid-sentinel-lymph-node-biopsy 2025-04-18T19:34:02+00:00 hourly 0.9 https://trial.medpath.com/news/e3b0e93ff26b54ad/notch1-mutations-predict-superior-immunotherapy-response-in-advanced-esophageal-cancer 2025-04-18T18:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/be9136bcd61b36b0/zydus-medtech-partners-with-braile-biomedica-to-expand-tavi-technology-across-europe-and-india 2025-04-18T18:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/a821511023363864/fda-approves-genus-pic-s-gene-edited-prrs-resistant-pigs-in-landmark-decision 2025-04-18T18:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/03ff84e145bc266a/long-term-disease-control-observed-in-nsclc-patients-after-immune-checkpoint-inhibitor-discontinuation 2025-04-18T18:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/db81df0bbaaf41c5/fda-grants-breakthrough-device-designation-to-alibaba-s-ai-for-early-pancreatic-cancer-detection 2025-04-18T18:46:32+00:00 hourly 0.9 https://trial.medpath.com/news/74f2e20f83a08007/real-world-study-shows-pepaxti-effective-in-heavily-pretreated-multiple-myeloma-patients 2025-04-18T18:45:29+00:00 hourly 0.9 https://trial.medpath.com/news/29738e69e325283c/early-discontinuation-of-adjuvant-immunotherapy-shows-no-negative-impact-on-melanoma-recurrence 2025-04-18T18:45:26+00:00 hourly 0.9 https://trial.medpath.com/news/9ce5fee3fdb0878e/nebraska-becomes-first-state-to-ban-soda-and-energy-drinks-from-snap-program 2025-04-18T18:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/3c6d3caa665dace1/trump-administration-cancels-800-million-in-lgbtq-health-research-funding 2025-04-18T18:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/1ed0408e7eeb31e1/women-with-autoimmune-diseases-face-50-higher-risk-of-heart-related-death-than-men 2025-04-18T18:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/baccadb82d6af973/fda-recalls-six-acne-products-after-testing-reveals-benzene-contamination-above-safety-limits 2025-04-18T18:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/ce61f91f160fd5d1/u-s-measles-outbreak-intensifies-600-cases-reported-as-hhs-secretary-s-stance-on-vaccines-draws-criticism 2025-04-18T18:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/7dffbc6ef867ad76/ob-gyn-workforce-shifts-following-abortion-bans-new-study-reveals-complex-migration-patterns 2025-04-18T18:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/0c5cad5e17ec5d30/cdc-reinstates-460-laid-off-employees-amid-ongoing-organizational-turmoil 2025-04-18T18:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/21260c770302b4d5/trump-administration-slashes-10000-hhs-jobs-amid-major-restructuring 2025-04-18T18:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/578acc9928d565c6/cancer-screening-rates-rebound-post-pandemic-but-cervical-cancer-prevention-lags-behind 2025-04-18T18:26:52+00:00 hourly 0.9 https://trial.medpath.com/news/378b910c22cffec4/ipsen-secures-dual-chmp-approvals-for-rare-liver-disease-treatments-following-regulatory-strategy-shift 2025-04-18T18:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/32cdc7d58a933306/trump-administration-reverses-decision-to-end-free-covid-19-test-program 2025-04-18T18:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/12ff4d4bbc0e9640/evidence-review-finds-limited-effective-treatments-for-low-back-pain 2025-04-18T18:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/d7ab3ecb5d282149/glp-1-drugs-linked-to-elevated-risk-of-serious-eye-conditions-in-multiple-studies 2025-04-18T18:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/0ceaeccf31d96eca/heart-disease-mortality-patterns-shift-as-acute-deaths-decline-while-chronic-conditions-rise 2025-04-18T18:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/06a8876906da3273/heavy-cannabis-use-linked-to-triple-mortality-risk-and-rising-psychosis-cases-studies-find 2025-04-18T18:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/0590293413de2d1a/declining-childhood-vaccination-rates-raise-alarm-for-resurgence-of-preventable-diseases 2025-04-18T18:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/12a2988f860089e4/medicare-expands-drug-price-negotiations-to-include-15-high-cost-medications-including-ozempic-and-wegovy 2025-04-18T18:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/db46742235d9371f/blood-test-predicts-rapid-alzheimer-s-decline-using-insulin-resistance-marker 2025-04-18T18:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/3c50ce96993c0953/risk-reducing-surgeries-significantly-improve-survival-in-brca-positive-breast-cancer-patients 2025-04-18T18:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/822960045fc92987/blood-test-innovations-cbc-analysis-could-revolutionize-disease-detection-and-monitoring 2025-04-18T18:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/b27261338af21fcd/alcohol-and-substance-use-linked-to-rising-e-scooter-injuries-studies-show 2025-04-18T18:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/a10af96cb9140fb9/loneliness-epidemic-shifts-middle-aged-americans-more-isolated-than-seniors-new-research-reveals 2025-04-18T18:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/936f321f3f85e9d9/high-fiber-plant-based-diet-shows-promise-in-preventing-multiple-myeloma-progression-in-at-risk-patients 2025-04-18T18:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/fe878493f1236dfc/expert-guidance-for-managing-holiday-activities-with-dementia-patients-practical-approaches-for-caregivers 2025-04-18T18:01:08+00:00 hourly 0.9 https://trial.medpath.com/news/9d95c1d10162b37a/radnet-to-acquire-icad-for-100-million-advancing-ai-powered-breast-cancer-detection 2025-04-18T18:00:51+00:00 hourly 0.9 https://trial.medpath.com/news/789c5499f9b29945/california-child-tests-positive-for-h5n1-bird-flu-without-known-animal-exposure 2025-04-18T17:59:54+00:00 hourly 0.9